Method for making and analyzing engineered cells

Gene signatures for donor cells enhance the persistence and functionality of engineered T cells, addressing immune rejection and tumor suppression issues in allogeneic CAR T therapies, improving cancer treatment efficacy.

WO2026236528A1PCT designated stage Publication Date: 2026-11-12ALLOGENE THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/027152
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-07
Filing Date
2026-05-07
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

The limited persistence of engineered T cells in allogeneic CAR T cell therapies is hindered by immune rejection and tumor microenvironment suppression, necessitating improved methods to identify and select immune cell populations for effective treatment.

Method used

The use of gene signatures, detected through methods like qRT-PCR and flow cytometry, to identify and select donor cell populations with specific upregulated and downregulated genes, enhancing the in vivo persistence and functionality of engineered T cells.

Benefits of technology

This approach improves the manufacturing process and persistence of engineered T cells, enabling effective treatment of cancers such as leukemia and lymphoma by selecting cells with improved cytotoxicity and reduced cytokine secretion.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000034_0001
    Figure IMGF000034_0001
  • Figure IMGF000048_0001
    Figure IMGF000048_0001
  • Figure IMGF000061_0001
    Figure IMGF000061_0001
Patent Text Reader

Abstract

Provided herein are methods, kits and reagents for analyzing the attributes of cell populations, such as donor cells prior to modification to provide engineered cells, e.g., engineered immune cells, such as CAR T cells. For example, provided herein are methods of determining the amount or percentage of a cell population expressing a gene signature associated with preferential expansion in vivo. Methods are provided for selecting donor cells with certain gene signatures associated with preferential expansion in vivo for engineering CAR T cell therapies.
Need to check novelty before this filing date? Find Prior Art

Description

METHOD FOR MAKING AND ANALYZING ENGINEERED CELLSCROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to a U. S. Provisional Application Ser. No.63 / 801,601 filed on May 7, 2025.BACKGROUND

[0002] Chimeric antigen receptor (CAR) T cell therapy has achieved unprecedented success, yet manufacturing of CAR T cells also presents unprecedented challenges. CAR T cells derived from a patient's own cells (autologous CAR T cells) have disadvantages including delays in treating patients and the inability to treat all patients due to manufacturing failures stemming from dysfunctional T cells present in this patient population. In contrast, CAR T cells derived from allogeneic donor cells (allogeneic CAR T cells) can be produced as off-the-shelf products with reduced costs and simplified manufacturing process as compared to autologous CAR T cells. Allogeneic CAR T cell therapy uses T cells from healthy individuals as starting material, simplifying supply, and providing off-the-shelf product convenience. A major hurdle in developing allogeneic engineered T-cell therapies, like CAR T therapies, is the limited persistence of the engineered T cells within the recipient's body. This lack of persistence can be attributed to several factors, including rejection by the host's immune system and the suppressive effects of the tumor microenvironment. There is a need for methods and reagents to identify and select immune cell populations for use in allogenic CAR T cell therapies.SUMMARY

[0003] In one aspect, the disclosure provides an immunotherapy composition, comprising an effector T cell population, wherein the cell populations comprises cells expressing, detectable as a polynucleotide and / or a protein, one or more upregulated genes of upregulated genes provided in Table 19A or one or more downregulated genes of downregulated genes provided in Table 19B.

[0004] In some embodiments, the one or more genes of Table 19A are each independently expressed at a level higher than a control level of expression in a control cell population having lower potency than the effector T cell population.

[0005] In some embodiments, the one or more genes of Table 19B are each independently expressed at a lower level than a control level of expression in a control cell population having lower potency than the effector T cell population.

[0006] In some embodiments, the one or more upregulated genes and the one or more downregulated genes comprises at least set of genes in a numbered row of Table 21A, Table 21B, Table 21C, and Table 21D

[0007] In some embodiments, the effector T cell population comprises at least 5 percent (%) or between about 1 % and 10 % of cells expressing the one or more genes.

[0008] In some embodiments, the effector T cell population is a chimeric antigen receptor T (CAR T) cell population.

[0009] In some embodiments, the expression one or more genes is detectable as polynucleotide, optionally by quantitative reverse transcription polymerase chain reaction (qRT-PCR).

[0010] In some embodiments, the expression of one or more genes is detectable as protein, optionally by flow cytometry.

[0011] In some embodiments, the effector T cell population has improved in vitro functionality as compared to an additional effector memory T cell population that does not express one or more of upregulated genes provided in Table 19A and / or that does express one or more of downregulated genes provided in Table 19B.

[0012] In some embodiments, the improved in vitro functionality comprises one or more of improved in vitro cytotoxicity, improved cell fitness, and reduced cytokine secretion.

[0013] In some embodiments, the cytotoxicity is demonstrated by an in vitro killing assay.

[0014] In some embodiments, the cytotoxicity is demonstrated by in vitro killing assay that comprises killing of cells that express a target of a CAR.

[0015] In some embodiments, the in vitro killing assay is a long-term killing assay.

[0016] In some embodiments, the in vitro killing assay is a short-term killing assay.

[0017] In some embodiments, the effector T cell population is an effector memory' T cell population.

[0018] The disclosure provides a method of treating a disease or disorder in a patient in need thereof, comprising administering to the patient any composition disclosed herein.

[0019] In some embodiments, the patient has, or is suspected of having, cancer.

[0020] In some embodiments, the cancer is selected from the group consisting of leukemia, lymphoma, multiple myeloma, melanoma, breast cancer, lung cancer, colorectal cancer, pancreatic cancer, ovarian cancer, prostate cancer, and glioblastoma.

[0021] In some embodiments, the disclosure further provides a method of selecting a donor cell population, comprising: detecting in a plurality of donor cell populations one or more genes of upregulated genes provided in Table 19A or downregulated genes provided in Table 19B or a set of upregulated and downregulated genes provided in Table 21A, Table 21B, Table 21C, and Table 21D; and selecting at least one donor cell population from the plurality as having: detectable expression of the one or more genes or set of genes, higher expression of the one or more upregulated genes or set of upregulated genes and / or lower expression of the one or more downregulated genes or set of downregulated genes than a reference cell population, and / or higher expression of the one or more upregulated genes or set of upregulated genes and / or lower expression of the one or more downregulated genes or set of downregulated genes than other members of the plurality.

[0022] In some embodiments, the method comprises, before the selecting of at least one donor cell population, introducing a polynucleotide sequence encoding an exogenous gene.

[0023] In some embodiments, the exogenous gene comprises a chimeric antigen receptor (CAR).

[0024] In some embodiments, the CAR comprises a transmembrane domain, a costimulatory domain and a signaling domain.

[0025] In some embodiments, the method comprises, after the selecting of at least one donor cell population, introducing a polynucleotide sequence encoding an exogenous gene.

[0026] In some embodiments, the exogenous gene comprises a chimeric antigen receptor (CAR).

[0027] In some embodiments, the CAR comprises a transmembrane domain polynucleotide sequence, a costimulatory domain polynucleotide sequence and a signaling domain polynucleotide sequence.

[0028] In some embodiments, the expression of one or more genes is detectable as polynucleotide, optionally by quantitative reverse transcription polymerase chain reaction (qRT-PCR).

[0029] In some embodiments, the expression of one or more genes is detectable as protein, optionally by flow cytometry'.

[0030] In some embodiments, the disclosure further provides a method of manufacturing engineered immune cells comprising: detecting in a plurality of immune cell populations one or more genes of upregulated genes provided in Table 19A or downregulated genes provided in Table 19B or a set of upregulated and downregulated genes provided in Table 21A, Table21 B, Table 21 C, and Table 21 D; and selecting at least one immune cell population from the plurality as having: detectable expression of the one or more genes or set of genes, higher expression of the one or more upregulated genes or set of upregulated genes and / or lower expression of the one or more downregulated genes or set of downregulated genes than a reference cell population, and / or higher expression of the one or more upregulated genes or set of upregulated genes and / or lower expression of the one or more downregulated genes or set of downregulated genes than other members of the plurality wherein the selected immune cell population is modified to express an exogenous nucleic acid.

[0031] In some embodiments, the exogenous nucleic acid comprises a chimeric antigen receptor (CAR) nucleic acid sequence.

[0032] In some embodiments, the CAR nucleic acid sequence comprises a transmembrane domain nucleic acid sequence, a costimulatory domain nucleic acid sequence and a signaling domain nucleic acid sequence.

[0033] In some embodiments, the expression of one or more genes is detectable as polynucleotide, optionally by quantitative reverse transcription polymerase chain reaction (qRT-PCR).

[0034] In some embodiments, the expression of one or more genes is detectable as protein, optionally by flow cytometry.

[0035] In some embodiments, the engineered immune cells are T cells.

[0036] In some embodiments, the T cells are CAR T cells.

[0037] In some embodiments, the T cells are effector memory T cells.BRIEF DESCRIPTION OF THE DRAWINGS

[0038] The fde of this patent contains at least one drawing executed in color. Copies of this patent with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

[0039] FIG. 1A is a Uniform Manifold Approximation and Projection (UMAP) showing the infusion product (IP) single cell data and highlights clusters enriched with expanding clones from Anti-CD19 CAR T IP lot 1.

[0040] FIG. IB is a Uniform Manifold Approximation and Projection (UMAP) showing the IP single cell data and highlights clusters enriched with expanding clones from AntiCD 19 CAR T IP lot 2.

[0041] FIG. 1C is a Uniform Manifold Approximation and Projection (UMAP) showing the IP single cell data and highlights clusters enriched with expanding clones from AntiCD 19 CAR T IP lot 3.

[0042] FIG. ID is a Uniform Manifold Approximation and Projection (UMAP) showing the IP single cell data and highlights clusters enriched with expanding clones from Anti-BCMA CAR T IP lot 1.

[0043] FIG. IE is a Uniform Manifold Approximation and Projection (UMAP) showing the IP single cell data and highlights clusters enriched with expanding clones from Anti-BCMA CAR T IP lot 2.

[0044] FIG. IF is a heat map showing the relative RNA expression of the shared expanding clone signature identified across 5 lots.

[0045] FIG. 1G is a scatter plot showing the genes that are significantly upregulated or down regulated at the RNA level in expanding clones in Anti-CD19 Lot3 compared to AntiCD 19 Lot 1. Sig_both signifies the gene is significantly changed at the RNA level in both Anti-CD19 Lot3 and Anti-CD19 Lot 1. Sig_ Anti-CD19 Lot 1 signifies the gene is significantly changed at the RNA level in Anti-CD19 Lot 1. Sig_ Anti-CD19 Lot 3 signifies the gene is significantly changed at the RNA level in Anti-CD19 Lot 3.

[0046] FIG. 1H is a heat map showing the relative Protein expression of the shared expanding clone signature identified across 5 lots.

[0047] FIG. II is a scatter plot showing the genes that are significantly upregulated or down regulated at the Protein level in expanding clones in Anti-CD19 Lot3 compared to Anti-CD19 Lot 1. Sig both signifies the gene is significantly changed at the Protein level in both Anti-CD19 Lot3 and Anti-CD19 Lot 1. Sig_ Anti-CD19 Lot 1 signifies the gene is significantly changed at the Protein level in Anti-CD19 Lot 1. Sig_ Anti-CD19 Lot 3 signifies the gene is significantly changed at the Protein level in Anti-CD19 Lot 3.

[0048] FIG. 2A is a graph showing the percentage of preferentially expanding clones in the blood out of all detected IP clones in post-infusion clear cell renal cell carcinoma (ccRCC) biopsy samples from patients infused with the anti-CD70 CAR T.

[0049] FIG. 2B is a Venn diagram showing the overlap of the preferentially expanding clones present in the tumor and in blood. Majority of IP clones expanding in tumors are also expanding in blood in post-infusion clear cell renal cell carcinoma (ccRCC) biopsy samples from patients infused with the anti-CD70 CAR T.

[0050] FIG.2C is a composite figure showing that infusion product (IP) clones identified in tumor samples are predominantly associated with an effector memory and / or preferentially expanding clone phenotype.

[0051] FIG.2D is a composite figure showing that infusion product (IP) clones identified in bone marrow aspirate samples are predominantly associated with an effector memory and / or preferentially expanding clone phenotype.

[0052] FIG. 3A is a Uniform Manifold Approximation and Projection (UMAP) showing the 52-gene signature identifies the IP single cell clusters that are in enriched in expanding clones of anti-CD19 IP Lot 1.

[0053] FIG.3B is a Uniform Manifold Approximation and Projection (UMAP) showing the 52-gene signature identifies the IP single cell clusters that are in enriched in expanding clones of anti-CD70 IP Lot 1.

[0054] FIG. 3C is a Uniform Manifold Approximation and Projection (UMAP) showing the 52-gene signature identifies the IP single cell clusters that are in enriched in expanding clones of anti-CD70 IP Lot 2.

[0055] FIG.4A is a graph showing the Precision-Recall Area Under the Curve (PR AUC) for anti-CD19 allogenic CAR T cells Lot 1 analyzed with the 52 gene signature.

[0056] FIG.4B is a graph showing the Precision-Recall Area Under the Curve (PR AUC) for anti-CD70 allogenic CAR T cells Lot 1 analyzed with the 52 gene signature.

[0057] FIG.4C is a graph showing the Precision-Recall Area Under the Curve (PR AUC) for anti-CD70 allogenic CAR T cells Lot 2 analyzed with the 52 gene signature.

[0058] FIG.5A is a graph showing the Precision-Recall Area Under the Curve (PR AUC) for anti-CD19 allogenic CAR T cells Lot 1 analyzed with the 16 gene signature.

[0059] FIG.5B is a graph showing the Precision-Recall Area Under the Curve (PR AUC) for anti-CD70 allogenic CAR T cells Lot 1 analyzed with the 16 gene signature.

[0060] FIG. 5C is a Uniform Manifold Approximation and Projection (UMAP) showing the 16-gene signature identifies the IP single cell clusters that are in enriched in expanding clones of anti-CD19 IP Lot 1.

[0061] FIG. 5D is a Uniform Manifold Approximation and Projection (UMAP) showing the 16-gene signature identifies the IP single cell clusters that are in enriched in expanding clones of anti-CD70 IP Lot 2.

[0062] FIG. 6A is a composite figure showing that cells identifiable in donor peripheral blood mononuclear cell (PBMC) populations have phenotypic characteristics similar to cellsidentified in engineered immune cell populations and / or drug product populations, including shared expression features associated with preferentially expanding clones.

[0063] FIG. 6B is a composite figure showing that preferentially expanding clone phenotypes in donor PBMCs and engineered immune cell populations are associated with markers characteristic of effector memory and / or terminal effector-like T-cell populations, optionally including one or more of CD57, CD45RO, CD45RA, CD27, and CD73.

[0064] FIG. 6C is a composite figure showing that the disclosed gene signature, including the 52-gene signature, identifies preferentially expanding clone cells in donor PBMC populations and can be used to detect, track, quantify, and / or isolate such cells in donor material and engineered immune cell populations.DETAILED DESCRIPTION

[0065] The instant disclosure relates to methods and reagents for analyzing cell populations, such as engineered cell populations and / or, donor cell populations to identify immune cell populations for treating patients, to improve manufacturing of engineered cell populations and / or improve the manufacturing process for engineered cell populations. The methods and reagents for analyzing immune cell populations disclosed herein provide gene signatures that mark immune cell populations for treating patients that preferentially expand in vivo. The methods and reagents for analyzing immune cell populations disclosed herein can be used to identify donor cells within a donor cell population for treating patients that preferentially expand in vivo to improve manufacturing of engineered cell populations. The methods and reagents for analyzing immune cell populations disclosed herein can be used to identify donor cells within a donor cell population for treating patients that preferentially expand in vivo to improve the manufacturing process for engineered cell populations. The methods and reagents for analyzing immune cell populations disclosed herein can be used to identify engineered immune cells with an engineered immune cell population that preferentially expand in vivo to improve manufacturing of engineered cell populations. The methods and reagents for analyzing immune cell populations disclosed herein can be used to identify engineered immune cells with an engineered immune cell population that preferentially expand in vivo to improve the manufacturing process for engineered cell populations.

[0066] Provided herein are methods and reagents for analysis and / or characterization of cell populations, such as engineered immune cell populations (e.g. CAR T cell populations). The methods and reagents disclosed herein allow for the identification of engineered immunecell populations based on one or more attributes, which if present, results in preferential expansion in vivo compared to engineered immune cells that do not have the one or more attributes. Also provided herein are processes, workflows, kits, articles of manufacture and reagents that allow reliable and convenient analysis of critical attributes of engineered immune cell populations.

[0067] In addition, the instant disclosure provides methods and reagents for analysis and / or characterization of cell populations, such as donor cell populations, including w ithout limitation donor immune cell populations, for example peripheral blood mononuclear cells (PBMCs), for use in selecting donor cells for manufacturing of engineered cell populations, e.g., engineered immune cell populations, such as CAR T cell populations. The methods and reagents disclosed herein allow for the identification of donor cell populations based on one or more attributes, which if present, results in preferential expansion in vivo in engineered cell populations that are derived from the donor cells as compared to engineered cell populations that are derived from donor cell populations that do not have the one or more attributes. Also provided herein are processes, workflows, kits, articles of manufacture and reagents that allow reliable and convenient analysis of critical attributes of donor cell populations.Atributes of Cell Populations

[0068] In one aspect, the instant disclosure concerns the detection, identification, and / or selection of cells from a cell population, such as engineered immune cells from an engineered immune cell population that have the desired attributes after manufacturing.

[0069] In another aspect, the instant disclosure concerns the detection, identification, and / or selection of cells from a cell population, such as donor cells from a donor cell population, that have desired attributes prior to modification of such cells to manufacture engineered cells, e.g., prior to modification of donor cells to manufacture CAR T cell products.

[0070] The methods and reagents disclosed herein allow for the identification of cell populations, e.g., engineered immune cells or donor cell populations, based on one or more attributes, which if present, correlate to preferential expansion in vivo for engineered cell populations (e.g., engineered immune cell populations) that are derived from the cells (e.g., donor cells) compared to cell populations that do not have the one or more attributes. One or more attributes may be used to screen cell populations (e.g., engineered immune cell populations) including, without limitation, detection of the presence or absence of one ormore of the gene signatures as described herein. In addition, engineered cells (e.g., engineered immune cells, such as CAR T cells) derived from donor cells may be subjected to the same detection, identification, and / or selection methods based on the same or different attributes that were analyzed in the donor cells.

[0071] In some embodiments, the cells identified in donor peripheral blood mononuclear cell (PBMC) populations using the gene signatures disclosed herein exhibit phenotypic characteristics similar to those in preferentially expanding cells identified in engineered immune cell populations, including drug product and / or infusion product populations. In some embodiments, the shared phenotype indicates that a preferentially expanding clone phenotype pre-exists in donor material prior to engineering and expansion (FIG. 6A) and can be selected using the gene signatures disclosed herein.Gene Signature Detection

[0072] In one aspect, the present disclosure provides methods and reagents to screen or analyze cells from a cell population (e.g., engineered cells of an engineered cell population and / or donor cells of a donor cell population) for a percentage of cells from the cell population that express one or more of the gene signatures described herein. As used herein, the term “gene signature” refers to a defined set of genes whose collective expression pattern is characteristic of a particular biological state, cellular phenotype, disease condition, or treatment response. The gene signature may include genes that are upregulated, downregulated, or otherwise differentially expressed relative to a control or reference condition. The expression profile of the gene signature may be measured using any suitable assay disclosed herein, including but not limited to RNA sequencing (RNA-seq), quantitative reverse transcription PCR (qRT-PCR), microarray analysis, digital droplet PCR (ddPCR), Nanostring nCounter® technology, or single-cell transcriptomic methods. Additional methods for detecting the gene signatures disclosed herein include, flow cytometry, fluorescence activated cell sorting, (FACS) flow cytometry, an Enzyme-Linked Immunosorbent Assay (ELISA), an Enzyme-linked immuno-filtration assay (ELIFA), an immunoblotting assay, an immunofluorescence assay, an immunochemistry (IHC) assay, western blot analysis and immunoprecipitation, molecular binding assays

[0073] In embodiments, the gene signature comprises one or more of the genes in the 52 gene signature provided in Table 1 and any combination thereof. In embodiments, the gene signature comprises one or more of the genes in the 16 gene signature provided in Table 2 and any combination thereof. In embodiments, the gene signature comprises one or more ofthe genes in the 21 gene signature provided in Table 3 and any combination thereof. In embodiments, the gene signature comprises one or more of the genes in the 20 gene signature provided in Table 4 and any combination thereof. In embodiments, the gene signature comprises one or more of the genes in the 21 gene signature provided in Table 5 and any combination thereof. In embodiments, the gene signature comprises one or more of the genes in the 20 gene signature provided in Table 6 and any combination thereof. In embodiments, the gene signature comprises one or more of the genes in the 16 gene signature provided in Table 7 and any combination thereof. In embodiments, the gene signature comprises one or more of the genes in the 15 gene signature provided in Table 8 and any combination thereof. In embodiments, the gene signature comprises one or more of the genes in the 16 gene signature provided in Table 9 and any combination thereof. In embodiments, the gene signature comprises one or more of the genes in the 15 gene signature provided in Table 10 and any combination thereof. In embodiments, the gene signature comprises one or more of the genes in the 11 gene signature provided in Table 11 and any combination thereof. In embodiments, the gene signature comprises one or more of the genes in the 10 gene signature provided in Table 12 and any combination thereof. In embodiments, the gene signature comprises one or more of the genes in the 11 gene signature provided in Table 13 and any combination thereof. In embodiments, the gene signature comprises one or more of the genes in the 10 gene signature provided in Table 14 and any combination thereof. In embodiments, the gene signature comprises one or more of the genes in the 6 gene signature provided in Table 15 and any combination thereof. In embodiments, the gene signature comprises one or more of the genes in the 5 gene signature provided in Table 16 and any combination thereof. In embodiments, the gene signature comprises one or more of the genes in the 6 gene signature provided in Table 17 and any combination thereof. In embodiments, the gene signature comprises one or more of the genes in the 5 gene signature provided in Table 18 and any combination thereof.

[0074] In embodiments, the cells are characterized by the percentage of one or more of the genes listed in Tables 1-18 and any combination thereof. In embodiments, the gene signature comprises increased expression of one or more of the genes listed in Table 19A or Table 20A and any combination thereof. In embodiments, the gene signature comprises decreased expression of one or more of the genes listed in Table 19B or Table 20B and any combination thereof. As used herein, the term "combination" refers to any subset of elements selected from a defined group, unless explicitly stated otherwise. For example, acombination of genes from a gene signature comprising 52 genes may include any subset of 1, 2, 3, up to all 52 genes. A combination does not require the inclusion of all members of the defined group and may specifically exclude one or more individual elements of the group.

[0075] In other embodiments, the detected percentage of cells expressing one or more of the genes listed in Tables 1-18 and any combination thereof is between about 0% and about 100% of the cell population being analyzed. In other embodiments, the percentage of cells expressing one or more of the genes listed in Tables 1-18 is about 0%, about 1%, about 2%, about 3%, about 4%, about 5%, about 6%. about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%.

[0076] In other embodiments, the percentage of cells expressing one or more of the genes listed in Tables 1 -18 is at least 1 %, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 21%, at least 22%, at least 23%, at least 24%, at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, at least 59%, at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, at least73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%. at least 96%. at least 97%. at least 98%. or at least 99%.

[0077] In other embodiments, the percentage of cells expressing one or more of the genes listed in Tables 1-18 is between about 1% and 10% of the cells expressing the one or more genes. In other embodiments, the percentage of cells expressing one or more of the genes listed in Tables 1-18 is between about 10% and 20% of the cells expressing the one or more genes. In other embodiments, the percentage of cells expressing one or more of the genes listed in Tables 1-18 is between about 20% and 30% of the cells expressing the one or more genes. In other embodiments, the percentage of cells expressing one or more of the genes listed in Tables 1-18 is between about 30% and 40% of the cells expressing the one or more genes. In other embodiments, the percentage of cells expressing one or more of the genes listed in Tables 1-18 is between about 40% and 50% of the cells expressing the one or more genes. In other embodiments, the percentage of cells expressing one or more of the genes listed in Tables 1-18 is between about 50% and 60% of the cells expressing the one or more genes. In other embodiments, the percentage of cells expressing one or more of the genes listed in Tables 1-18 is between about 70% and 80% of the cells expressing the one or more genes. In other embodiments, the percentage of cells expressing one or more of the genes listed in Tables 1-18 is between about 80% and 90% of the cells expressing the one or more genes. In other embodiments, the percentage of cells expressing one or more of the genes listed in Tables 1-18 is between about 90% and 95% of the cells expressing the one or more genes. In other embodiments, the percentage of cells expressing one or more of the genes listed in Tables 1-18 is between about 95% and 99% of the cells expressing the one or more genes.

[0078] In another aspect, the methods, compositions, cell populations and kits concern the detection of, identification of, and / or screening of cells (e.g. engineered cells and / or donor cells) from cell populations (e.g. engineered cell populations and / or donor cell populations) for a level of expression of genes listed in Tables 1-18 as a percentage of the cell population being tested. Expression of the gene signature in certain cell populations can be predictive of the degree of in vivo expansion for engineered immune cells from an engineered immune cell population, e g., a CAR T cell population, derived from donor cells of a donor cell population.Table 1: List of Genes in the 52-gene signatureTable 2: List of Genes in the 16-gene signatureTable 3: List of Genes in the top 20-plus gene signatureTable 4: List of Genes in the top 20 median gene signatureTable 5: List of Genes in the top 20 mean plus gene signatureTable 6: List of Genes in the top 20 mean gene signatureTable 7: List of Genes in the top 15 median_plus gene signatureTable 8: List of Genes in the top 15 median gene signatureTable 9: List of Genes in the top 15 mean_plus gene signatureTable 10: List of Genes in the top 15 mean gene signatureTable 11: List of Genes in the top 10 median_plus gene signatureTable 12: List of Genes in the top 10 median gene signatureTable 13: List of Genes in the top 10 mean_plus gene signatureTable 14: List of Genes in the top 10 mean_ gene signatureTable 15: List of Genes in the top 5 median_plus gene signatureTable 16: List of Genes in the top 5 median_ gene signatureTable 17: List of Genes in the top 5 mean_plus gene signatureTable 18: List of Genes in the top 5 mean gene signature

[0079] The detection of one or more of the genes in the genes signatures described herein of cells from a cell population (e.g. engineered cells from an engineered cell population and / or donor cells from a donor cell population) may be performed using different methodologies including, without limitation, flow cytometry, fluorescence activated cell sorting, (FACS) flow cytometry, an Enzyme-Linked Immunosorbent Assay (ELISA), an Enzyme-linked immuno-filtration assay (ELIFA), an immunoblotting assay, an immunofluorescence assay, an immunochemistry (IHC) assay, western blot analysis and immunoprecipitation, molecular binding assays. Additional methods for detection of one or more of the genes in the genes signatures described herein of cells from a cell population include: RNA based methods ( e.g. RNA sequencing, quantitative reverse transcription polymerase chain reaction (qRT-PCR), NanoString nCoutner, microarrays, Droplet Digital PCT (ddPCR), and single cell methods ( e.g. Single cell RNA seq (scRNA-seq), Cellular indexing of Transcriptomes and Epitopes by Sequencing (CITE-seq).

[0080] Detection using Flow Cytometry: Instruments for particle analysis, e.g., flow and scanning cytometers, allow individual particles or cells (e.g., single engineered cells from an engineered cell population and / or single donor cells from a donor cell population) to be characterized using optical parameters such as light scatter and fluorescence. For example, a flow cytometer allows an aqueous suspension containing individual particles (e.g., beads comprising analytes of interest) or cells to be passed by a detection region that exposes the suspension to an excitatory light source, such as one or more lasers, thereby enabling a userto measure the light scattering and fluorescence properties of the particles or cells. The labeling of particles or cells with one or more fluorescent dyes can facilitate detection. A plurality of different particles or cells may be subjected to flow cytometry for simultaneous detection by using different dyes that are spectrally distinct to label different particles or cells. In other embodiments, multiple photodetectors can be deployed to measure different scatter parameters and / or different spectrally distinct dyes. For example, one or more detectors may be configured to measure one or more sets of scatter parameters and one or more additional detectors may be configured to measure one or more distinct dyes, which would allow the generation of data comprising signals for each light scatter parameter and each fluorescence emission.

[0081] Flow cytometry parameters that are commonly measured include, without limitation, (i) the excitation light that is scattered by the particle or cell along a mostly forward direction, or forward scatter (FSC), (ii) the excitation light that is scattered by the particle or cell in a mostly sideways direction, or side scatter (SSC), and (ii) the light emissions from fluorescent molecules in one or more channels (range of frequencies) of the spectrum or by the fluorescent dye that is primarily detected in that channel. In one embodiment, different cell types from a donor cell population can be identified by the FSC, SSC, and fluorescence emissions resulting from labeling various cell-surface proteins on the donor cells with dye-labeled antibodies.

[0082] The data obtained from an analysis of particles or cells (e.g., single donor cells from a donor cell population and / or single engineered cells from an engineered cell population) by multi-color flow cytometry are multidimensional, wherein each cell corresponds to a point in a multidimensional space defined by the parameters measured. Populations of cells or particles are identified as clusters of points in the data space. The identification of clusters and, thereby, populations can be carried out manually by drawing a gate around a population displayed in one or more 2-dimensional plots, referred to as “scatter plots” or “dot plots,” of the data. Alternatively, clusters can be identified, and gates that define the limits of the populations can be determined automatically. Flow cytometry is an important tool for the analysis and / or isolation of particle or cells (e.g., individual donor cells from a donor cell populations) and cellular analytes or constituents thereof. Therefore, it can be used in the context of engineered immune cell or donor cell analysis and / or isolation. In one embodiment, the present disclosure provides a method using a fluid stream to linearly space engineered immune cells from an engineered immune cell population ordonor cells from a donor cell population such that they pass individually through a detection apparatus. A single cell from the engineered immune cell or donor cell population can be distinguished from other cells by their location in the fluid stream and the presence of detectable markers. As a result, a flow cytometer can be used to detect one or more one or more of the genes in the genes signatures (as described herein) and / or generate a gene signature profile for an engineered cell population and / or a donor cell population. Such profiles may comprise a percentage of cells (as further described herein) expressing one or more one or more of the genes in the gene signatures described herein out of the total cell population that is being analyzed.

[0083] In another aspect, the instant disclosure provides a method of detecting cells from a cell population (e.g., engineered cells from an engineered cell population and / or donor cells from a donor cell population) by detecting a level of one or more cell surface proteins. Tables 1-18 indicate the genes in the gene signature that when expressed are present on the cell surface. In embodiments, flow cytometry can be used to detect the level of expression of one or more cell surface proteins that are encoded by one or more of the genes of the gene signatures described herein. In one embodiment, the detected level indicates that some of the cells (e.g., engineered cells and / or donor cells) express the one or more cell surface proteins of the gene signature. In other embodiments, the detected level indicates that some of the cells express a first cell surface protein and / or some of the cells express a second cell surface protein of the gene signature. In one embodiment, the detected level indicates that some of the cells (e.g., engineered cells and / or donor cells) do not express the one or more cell surface proteins of the gene signature. In other embodiments, the detected level indicates that some of the cells do not express a first cell surface protein and / or some of the cells express a second cell surface protein of the gene signature. In some embodiments, the cells express one or more cell surface markers listed in Tables 1-18 or any combination thereof. In another aspect, the level of one or more cell surface proteins that is detected indicates the number of cells (e.g., engineered cells and / or donor cells) expressing the one or more cell surface proteins out of the cell population being analyzed (e.g. engineered cell population and / or donor cell population). Tables 1-18 provide additional cell surface proteins of the gene signatures for engineered cells of engineered cell populations and donor cells of donor cell populations.

[0084] In some embodiments, the method provides a quantitative measurement of engineered immune cells from an engineered immune cell population that express or express increased amounts of the cell surface proteins listed in Table 19A and Table 20A or anycombination thereof. In some embodiments, the method provides a quantitative measurement of engineered immune cells from an engineered immune cell population that do not express or express reduced amounts of the cell surface proteins listed in Table 19B and Table 20B or any combination thereof. Flow cytometry can be used to quantify cells expressing or not expressing specific surface markers, or quantifying cells of a specific cell type, within a population of cells.Table 19A: 52 gene set upregulatedTable 19B: 52 gene set down regulated

[0085] As described herein, flow cytometry is a method for quantifying components or structural features of cells primarily by optical means using certain labeling agents (as further described herein). Since different cell types can be distinguished by quantifying structural features, flow cytometry and cell sorting can be used to count and sort cells of different phenotypes in a mixture. A flow cytometry analysis involves two primary steps: 1) labeling selected cell types with one or more detectable labels or agents, and 2) determining the number of labeled cells relative to the total number of cells in the population. In some embodiments, the method of labeling cell types includes binding labeled antibodies to markers expressed by the specific cell type. The antibodies may be either directly labeled with a fluorescent compound or indirectly labeled using, for example, a fluorescent-labeled second antibody which recognizes the first antibody.Table 20A: 16 gene set upregulatedTable 20B: 16 gene set down regulated

[0086] In one other aspect, the present disclosure utilizes flow cytometry to provide methods for generating a gene signature for a cell population (e.g., a donor cell population or an engineered cell population) based on the percentage of one or more cel surface proteins detected. In one embodiment, the method comprises providing an engineered cell population, such as engineered immune cell population, or a donor cell population, such as donor immune cell population, that is suspected of comprising one or more cell surface markers of the gene signatures in Tables 1-18. In another embodiment, the method further comprises detecting a level of a first cell surface in the engineered immune cell population or the donor cell population, wherein the detected level of the first cell surface protein indicates that a percentage of the cell population expresses the first cell surface protein. In other embodiments, the first cell surface protein is any cell surface protein listed in Tables 1-18. In other embodiments, the method further comprises detecting a level of a second cell surface protein in the engineered immune cell population or the donor cell population wherein the detected level of the second cell surface protein indicates that a percentage of the cell population expresses the second cell surface protein. In another embodiment, the second cell surface protein is any cell surface protein listed in Tables 1-18. In some embodiments, the method comprises detecting levels of the first and second cell surface proteins, wherein the detected levels indicate a percentage expression in the engineered immune cell population or the donor cell population of the first cell surface protein and the second cell surface protein. In other embodiments, one or more additional cell surface proteins, e g., third, fourth, fifth, sixth, seventh, etc. Any combination of the cell surface proteins listed in Tables 1-18 can be used to generate additional gene signatures.Table 21A: List of Genes in the 20-gene signatureTable 21B: List of Genes in the 15-gene signatureTable 21C: List of Genes in the 10-gene signatureTable 21D: List of Genes in the 5-gene signature

[0087] As described herein, RNA sequencing (RNA-seq) can be used to detect and quantify the expression of genes with a specific gene signature by extracting total RNA from a cell population, converting the RNA into complementary DNA (cDNA), and sequencing the resulting library’ using high-throughput next-generation sequencing technologies. Sequencing reads are aligned to a reference genome or transcriptome, and expression levels for each gene in the signature are quantified, typically reported in transcripts per million (TPM) or fragments per kilobase per million reads (FPKM). This enables robust identification of upregulated or downregulated genes associated with a biological condition, treatment response, or cellular phenotype. In some embodiments, RNA seq is a method used to detect a gene signature described herein. In some embodiments, RNA-seq is used to detect the 52-gene signature disclosed in Table 1. In some embodiments, RNA-seq is used to detect the 16 gene signature disclosed in Table 2. In some embodiments, RNA-seq is used to detect any one of the gene signatures disclosed in Tables 1-18. and any combination thereof. RNA-seq can be used to detect a gene signature in donor cells in a donor cell population. RNA-seq can be used to detect a gene signature in donor cells in a donor cell population at any point during the isolation process. RNA-seq can be used to detect a gene signature in engineered immune cells in an engineered immune cell population. RNA-seq can be used to detect a gene signature in engineered immune cells in an engineered immune cell population at any point in the manufacturing process. RNA-seq can be used to detect a gene signature in engineered immune cells in an engineered immune cell population at any point in the treatment of a subject.

[0088] As described herein, quantitative reverse transcription polymerase chain reaction (qRT-PCR) can be used to assess expression of genes within a gene signature by first isolating RNA from a biological sample and converting it into complementary DNA (cDNA) using reverse transcription. Gene-specific primers are then used to amplify target genes in the cDNA through real-time PCR. where the accumulation of PCR product is measured in real time using a fluorescent dye or probe. The expression level of each gene in the signature is quantified relative to a reference gene using the AACt method or similar approach, enabling sensitive and specific detection of upregulated or downregulated genes in the sample. In some embodiments, qRT-PCR is a method used to detect a gene signature described herein. In some embodiments, qRT-PCR is used to detect the 52-gene signature disclosed in Table 1. In some embodiments, qRT-PCR is used to detect the 16 gene signature disclosed in Table 2. In some embodiments, qRT-PCR is used to detect any one of the gene signatures disclosed in Tables1-18, and any combination thereof. qRT-PCR can be used to detect a gene signature in donor cells in a donor cell population. qRT-PCR can be used to detect a gene signature in donor cells in a donor cell population at any point during the isolation process. qRT-PCR can be used to detect a gene signature in engineered immune cells in an engineered immune cell population. qRT-PCR can be used to detect a gene signature in engineered immune cells in an engineered immune cell population at any point in the manufacturing process. qRT-PCR can be used to detect a gene signature in engineered immune cells in an engineered immune cell population at any point in the treatment of a subject.

[0089] As described herein, The NanoString nCounter® system can be used to assess expression of genes within a gene signature by directly hybridizing barcoded probe pairs to target RNA molecules without the need for amplification. Total RNA is extracted from the biological sample and incubated with a custom CodeSet containing reporter and capture probes specific to each gene in the signature. After hybridization, the probe-target complexes are immobilized and individually counted using single-molecule imaging, providing a digital readout of transcript abundance. This method allows for multiplexed, precise, and reproducible quantification of gene expression across the entire signature or a subset of genes in the gene signature. In some embodiments. Nanostring nCounter is a method used to detect a gene signature described herein. In some embodiments, Nanostring nCounter is used to detect the 52-gene signature disclosed in Table 1. In some embodiments, Nanostring nCounter is used to detect the 16 gene signature disclosed in Table 2. In some embodiments, Nanostring nCounter is used to detect any one of the gene signatures disclosed in Tables 1-18, and any combination thereof. Nanostring nCounter can be used to detect a gene signature in donor cells in a donor cell population. Nanostring nCounter can be used to detect a gene signature in donor cells in a donor cell population at any point during the isolation process. Nanostring nCounter can be used to detect a gene signature in engineered immune cells in an engineered immune cell population. Nanostring nCounter can be used to detect a gene signature in engineered immune cells in an engineered immune cell population at any point in the manufacturing process. Nanostring nCounter can be used to detect a gene signature in engineered immune cells in an engineered immune cell population at any point in the treatment of a subject.

[0090] As used herein, droplet digital PCR (ddPCR) can be used to quantify expression levels of genes within a gene signature with high sensitivity and precision. In this method, RNA is first extracted from the biological sample and reverse-transcribed intocDNA. The cDNA is then partitioned into thousands of nanoliter-sized droplets, with PCR amplification occurring independently within each droplet. Fluorescently labeled probes specific to each gene in the signature enable detection and quantification of target transcripts. By counting the number of positive droplets for each gene, absolute transcript copy numbers can be determined without the need for standard curves, allowing for robust and accurate measurement of gene expression. In some embodiments, ddPCR is a method used to detect a gene signature described herein. In some embodiments, ddPCR is used to detect the 52-gene signature disclosed in Table 1. In some embodiments, ddPCR is used to detect the 16 gene signature disclosed in Table 2. In some embodiments, ddPCR is used to detect any one of the gene signatures disclosed in Tables 1-18, and any combination thereof. ddPCR can be used to detect a gene signature in donor cells in a donor cell population. ddPCR can be used to detect a gene signature in donor cells in a donor cell population at any point during the isolation process. ddPCR can be used to detect a gene signature in engineered immune cells in an engineered immune cell population. ddPCR can be used to detect a gene signature in engineered immune cells in an engineered immune cell population at any point in the manufacturing process. ddPCR can be used to detect a gene signature in engineered immune cells in an engineered immune cell population at any point in the treatment of a subject.

[0091] As used herein, Cellular Indexing of Transcriptomes and Epitopes by sequencing (CITE-seq) can be used to assess a gene signature by simultaneously measuring both mRNA expression and surface protein levels at the single-cell level. In this method, single cells are labeled with oligonucleotide-tagged antibodies targeting surface proteins and then subjected to single-cell RNA sequencing workflows. The oligonucleotide tags and cellular mRNA are co-captured, barcoded, and sequenced, allowing for integrated analysis of gene expression and protein phenotype in individual cells. This dual-modality approach enables precise characterization of cells expressing the gene signature and facilitates correlation of transcriptomic and proteomic data within heterogeneous cell populations. In some embodiments, CITE-seq is a method used to detect a gene signature described herein. In some embodiments, CITE-seq is used to detect the 52-gene signature disclosed in Table 1. In some embodiments, CITE-seq is used to detect the 16 gene signature disclosed in Table 2. In some embodiments, CITE-seq is used to detect any one of the gene signatures disclosed in Tables 1-18, and any combination thereof. CITE-seq can be used to detect a gene signature in donor cells in a donor cell population. CITE-seq can be used to detect a gene signature in donor cells in a donor cell population at any point during the isolation process. CITE-seq canbe used to detect a gene signature in engineered immune cells in an engineered immune cell population. CITE-seq can be used to detect a gene signature in engineered immune cells in an engineered immune cell population at any point in the manufacturing process. CITE-seq can be used to detect a gene signature in engineered immune cells in an engineered immune cell population at any point in the treatment of a subject.

[0092] In some embodiments, the methods for generating a gene signature profile further comprise steps to modify or select for modification a donor cell population that has been subjected to selection based on the expression of gene signature, such as by using flow cytometry. In one embodiment, the method further comprises modifying the donor cell population to express an exogenous nucleic acid sequence, thereby providing an engineered cell population. In additional embodiments, the engineered immune cell population comprises, exhibits, shows, or has preferential expansion in vivo as compared to an additional engineered immune cell population that originated from (or was originated from) an additional immune cell population that is negative for the gene signature. In other embodiments, the exogenous nucleic acid comprises a chimeric antigen receptor (CAR) nucleic acid sequence. The CAR sequence can include one or more nucleic acid sequences including, without limitation, a transmembrane domain nucleic acid sequence, a costimulatory domain nucleic acid sequence and a signaling domain nucleic acid sequence. In one embodiment, the exogenous nucleic acid sequence is expressed as a single transcript. In addition to or independent of the modification to express an exogenous nucleic acid sequence, the method may further comprise reducing or eliminating expression or activity of an endogenous gene, e.g., a T cell receptor gene (e.g., TCRa, TCR ) and / or CD52 as further described herein.

[0093] Prior to engineering, immune cell populations as described herein may be obtained from and / or derived from a donor prior to any gene signature detection steps. In some embodiments, the donor is a healthy donor or a patient need of treatment. The patient in need of treatment may be in need of treatment with an allogeneic cell therapy. In one embodiment, the allogeneic cell therapy may comprise engineered immune cell populations that were derived from healthy donor cells obtained from healthy individuals as starting material.

[0094] In some embodiments, the engineered immune cells and the donor cells comprising one or more of the gene signatures disclosed herein preferentially expand in vivo compared to engineered immune cells or donor cells that do not comprise one or more of thegene signatures disclosed herein. In some embodiments, the engineered immune cells or donor cells comprising one or more of the gene signatures disclosed herein proliferate 1% more than engineered immune cells or donor cells that do not comprise one or more of the gene signatures disclosed herein. In some embodiments, the engineered immune cells or donor cells comprising one or more of the gene signatures disclosed herein proliferate 10% more than engineered immune cells or donor cells that do not comprise one or more of the gene signatures disclosed herein. In some embodiments, the engineered immune cells or donor cells comprising one or more of the gene signatures disclosed herein proliferate 20% more than engineered immune cells or donor cells that do not comprise one or more of the gene signatures disclosed herein. In some embodiments, the engineered immune cells or donor cells comprising one or more of the gene signatures disclosed herein proliferate 30% more than engineered immune cells or donor cells that do not comprise one or more of the gene signatures disclosed herein. In some embodiments, the engineered immune cells or donor cells comprising one or more of the gene signatures disclosed herein proliferate 40% more than engineered immune cells or donor cells that do not comprise one or more of the gene signatures disclosed herein. In some embodiments, the engineered immune cells or donor cells comprising one or more of the gene signatures disclosed herein proliferate 50% more than engineered immune cells or donor cells that do not comprise one or more of the gene signatures disclosed herein. In some embodiments, the engineered immune cells or donor cells comprising one or more of the gene signatures disclosed herein proliferate 60% more than engineered immune cells or donor cells that do not comprise one or more of the gene signatures disclosed herein. In some embodiments, the engineered immune cells or donor cells comprising one or more of the gene signatures disclosed herein proliferate 70% more than engineered immune cells or the donor cells that do not comprise one or more of the gene signatures disclosed herein. In some embodiments, the engineered immune cells or donor cells comprising one or more of the gene signatures disclosed herein proliferate 80% more than engineered immune cells or the donor cells that do not comprise one or more of the gene signatures disclosed herein. In some embodiments, the engineered immune cells or donor cells comprising one or more of the gene signatures disclosed herein proliferate 90% more than engineered immune cells or the donor cells that do not comprise one or more of the gene signatures disclosed herein. In some embodiments, the engineered immune cells or donor cells comprising one or more of the gene signatures disclosed herein proliferate 100% more than engineered immune cells or the donor cells that do not comprise one or more ofthe gene signatures disclosed herein. In some embodiments, the engineered immune cells or donor cells comprising one or more of the gene signatures disclosed herein proliferate 150% more than engineered immune cells or the donor cells that do not comprise one or more of the gene signatures disclosed herein. In some embodiments, the engineered immune cells or donor cells comprising one or more of the gene signatures disclosed herein proliferate 200% more than engineered immune cells or the donor cells that do not comprise one or more of the gene signatures disclosed herein.

[0095] In some embodiments, the engineered immune cells or donor cells comprising one or more of the gene signatures disclosed herein proliferate at least 1% more than engineered immune cells or donor cells that do not comprise one or more of the gene signatures disclosed herein. In some embodiments, the engineered immune cells or donor cells comprising one or more of the gene signatures disclosed herein proliferate at least 10% more than engineered immune cells or donor cells that do not comprise one or more of the gene signatures disclosed herein. In some embodiments, the engineered immune cells or donor cells comprising one or more of the gene signatures disclosed herein proliferate at least 20% more than engineered immune cells or donor cells that do not comprise one or more of the gene signatures disclosed herein. In some embodiments, the engineered immune cells or donor cells comprising one or more of the gene signatures disclosed herein proliferate at least 30% more than engineered immune cells or donor cells that do not comprise one or more of the gene signatures disclosed herein. In some embodiments, the engineered immune cells or donor cells comprising one or more of the gene signatures disclosed herein proliferate at least 40% more than engineered immune cells or donor cells that do not comprise one or more of the gene signatures disclosed herein. In some embodiments, the engineered immune cells or donor cells comprising one or more of the gene signatures disclosed herein proliferate at least 50% more than engineered immune cells or donor cells that do not comprise one or more of the gene signatures disclosed herein. In some embodiments, the engineered immune cells or donor cells comprising one or more of the gene signatures disclosed herein proliferate at least 60% more than engineered immune cells or donor cells that do not comprise one or more of the gene signatures disclosed herein. In some embodiments, the engineered immune cells or donor cells comprising one or more of the gene signatures disclosed herein proliferate at least 70% more than engineered immune cells or donor cells that do not comprise one or more of the gene signatures disclosed herein. In some embodiments, the engineered immune cells or donor cells comprising one or more of the gene signatures disclosed herein proliferate at least80% more than engineered immune cells or donor cells that do not comprise one or more of the gene signatures disclosed herein. In some embodiments, the engineered immune cells or donor cells comprising one or more of the gene signatures disclosed herein proliferate at least 90% more than engineered immune cells or donor cells that do not comprise one or more of the gene signatures disclosed herein. In some embodiments, the engineered immune cells or donor cells comprising one or more of the gene signatures disclosed herein proliferate at least 100% more than engineered immune cells or donor cells that do not comprise one or more of the gene signatures disclosed herein. In some embodiments, the engineered immune cells or donor cells comprising one or more of the gene signatures disclosed herein proliferate at least 150% more than engineered immune cells or donor cells that do not comprise one or more of the gene signatures disclosed herein. In some embodiments, the engineered immune cells or donor cells comprising one or more of the gene signatures disclosed herein proliferate at least 200% more than engineered immune cells or donor cells that that do not comprise one or more of the gene signatures disclosed herein.

[0096] As described herein, the engineered cell population having a detected gene signature may be characterized by improved in vitro functionality, which can be improved in vitro cytotoxicity and / or improved in vitro cell fitness, e.g., in vitro mitochondrial fitness. Cytotoxicity can be demonstrated by an in vitro killing assay, such as an in vitro killing assay that comprises the killing of cells that express a target molecule that is recognized by the CAR. The in vitro killing assay may be an in vitro short-term killing assay (STKA) or an in vitro long-term killing assay (LTKA).

[0097] In another embodiment, the engineered immune cell population expressing one or more of the gene signatures disclosed herein may exhibit improved in vitro cytotoxicity as shown by an increased area under the curve or AUC. As used herein, the term “area under the curve'’ or “AUC” refers to a quantified measurement of both persistence (length of assay) and cytotoxicity (% killing) for LTKA. In the context of a STKA. “AUC” refers to a quantified measurement of cytotoxicity at different tumor burdens (distance between different effector-to-target ratio as 1). STKA and LTKA AUC can be measured as described in Example 5.

[0098] In some embodiments, the AUC is a STKA AUC or a LTKA AUC. In other embodiments, the LTKA AUC is between about 100 and about 2000. In another embodiment, the LTKA AUC is between about 200 and about 1500, between about 225 and about 1475, between about 225 and about 1475, between about 250 and about 1450, between about 275and about 1425, between about 300 and about 1400, between about 325 and about 1375, between about 325 and about 1350, between about 350 and about 1325, between about 350 and about 1300, between about 375 and about 1275, between about 400 and about 1250, between about 375 and about 1225, between about 400 and about 1250, between about 425 and about 1275, between about 450 and about 1200, between about 475 and about 1175, between about 500 and about 1150, between about 525 and about 1125, between about 550 and about 1100, between about 575 and about 1075, between about 600 and about 1050, or between about 625 and about 1025. In other embodiments, the LTKA AUC is between about 700 and about 1250, between about 725 and about 1250, between about 750 and about 1250, between about 775 and about 1250, between about 800 and about 1250, between about 825 and about 1250, between about 850 and about 1250, between about 875 and about 1250, between about 900 and about 1250, between about 925 and about 1250, between about 950 and about 1250, between about 975 and about 1250, between about 1000 and about 1250, between about 1025 and about 1250, between about 1050 and about 1250, between about 1075 and about 1250, between about 1100 and about 1250, between about 1125 and about 1250, between about 1150 and about 1250, between about 1175 and about 1250, between about 1200 and about 1250, or between about 1225 and about 1250. In some embodiments, the LTKA AUC is at least about 1100, at least about 1125, at least about 1150, at least about 1175, at least about 1200, at least about 1225, at least about 1250, at least about 1275, at least about 1300, at least about 1325, at least about 1350, at least about 1375, at least about 1400, at least about 1425. at least about 1450, at least about 1475, or at least about 1500.

[0099] In another embodiment, the in vitro functionality is in vitro cell fitness, e.g., mitochondrial fitness. Mitochondrial fitness can be measured by spare respiratory capacity (SRC) as described in Example 5. In one embodiment, the engineered immune cell population or donor cell population expressing one or more of the gene signatures disclosed herein exhibits improved mitochondrial fitness as shown by an increased SRC compared to engineered immune cell population or donor cell population not expressing one or more of the gene signatures disclosed herein. In embodiments, the SRC is about 25, about 30, about 35, about 40, about 45, about 50, about 55, about 60, about 65, about 70, about 75, about 80, about 85, about 90, about 95. or about 100.

[0100] Enrichment or depletion. In one other aspect, the instant disclosure provides methods and compositions for the enrichment and / or depletion of cells from a cell population (e.g., engineered cells from an engineered cell population and / or donor cells from a donorcell population) based on the observed associations (positive or negative) between the gene signatures described herein and the preferential expansion in vivo of engineered cells, e.g., CAR T cells, derived from such donor cells. In one embodiment, a method of enrichment is provided including the step of providing engineered immune cells from an engineered immune cell populations or donor cells from a donor cell population, wherein the enriched immune cell population comprises cells that express upregulated amounts of one or more genes listed in Table 19A or Table 20A. In one embodiment, a method of enrichment is provided including the step of providing engineered immune cells from an engineered immune cell populations or donor cells from a donor cell population, wherein the enriched immune cell population comprises cells that express reduced amounts of one or more down regulated genes of downregulated genes provided in genes listed in Tables 3B or Table 20B. In one embodiment, a method of depletion is provided including the step of providing engineered immune cells from an engineered immune cell populations or donor cells from a donor cell population, wherein the depleted immune cell population comprises cells that express reduced amounts of one or more of the upregulated genes of upregulated genes listed in Table 19A or Table 20A. In one embodiment, a method of depletion is provided including the step of providing engineered immune cells from an engineered immune cell populations or donor cells from a donor cell population, wherein the depleted immune cell population comprises cells that express increased amounts of one or more of the downregulated genes of downregulated genes listed in Tables IB or Table 20B.

[0101] According to the instant disclosure, the enrichment and / or depletion of cells from engineered cells or donor cells may be performed using flow cytometry approaches. The isolation of particles or cells (e.g., engineered cells from an engineered cell population and / or donor cells from a donor cell population) may be achieved by the addition of a sorting or collection function to a flow cytometer. Particles or cells that are spaced in a fluid stream may be detected as having one or more desired characteristics and subsequently isolated based on the detected characteristic(s) for each individual particle or cell. Particles or cells can be individually isolated from the stream by mechanical or electrical removal.

[0102] In one aspect, the instant disclosure provides methods and reagents for the removal of unwanted cells from a cell population (e.g., unwanted donor cells from a donor cell population and / or unwanted engineered cells from an engineered cell population) in a process of cell depletion. The unwanted cells can be depleted based on their lack of expression of the one or more of the genes signature provided herein. Initially, cells from a cellpopulation are exposed to one or more depletion reagents. In some embodiments, the depletion reagent(s) comprises an antibody targeting a cell surface protein expressed on engineered immune cells or donor cells such as one or more cell surface markers listed in Tables 1-18 or any combination thereof.

[0103] The enrichment or depletion antibody, or any other antibody can be conjugated, for example, to biotin to facilitate further labeling and / or separation using a secondary antibody (e.g., an anti-biotin antibody). The secondary7antibody can be conjugated either directly or indirectly with a magnetic depletion reagent such as magnetic depletion agent such as magnetic microbeads (nanoparticles that are generally, but not necessarily, about 50nm in diameter) or any other surface, such as an agarose bead, an acoustic wave particle, a plastic welled plate, a glass welled plate, a ceramic welled plate, a column, a cell culture bag, or a membrane. When magnetic microbeads are used, the microbeads facilitate separation of the cells positive for the cell surface protein in the gene signature from the cells negative for the cell surface protein in the gene signature; when contacted with a magnetic column, the gene signature positive cells can be retained on the column while unlabeled gene signature negative cells pass through to a collection bag. Acoustic wave particles can facilitate separation of gene signature-positive from the gene signature negative cells when exposed to an acoustic wave. While an anti-biotin antibody is provided in the context of the disclosed method, other biotin-binding partners such as streptavidin, avidin, and other proteins that recognize biotin can be employed in lieu of an anti-biotin antibody in all the methods provided herein.

[0104] In some embodiments, the antibody specific for the cell surface protein in the gene signature is optionally conjugated to a fluorophore. In this embodiment, the step of sorting or selecting the donor cells that bind to the antibody (e.g., a monoclonal antibody) can be done by Fluorescence Activated Cell Sorting (FACS).

[0105] In some other embodiments, the antibody specific for the cell surface protein in the gene signature is optionally conjugated to a magnetic particle. In this embodiment, the step of sorting or selecting the cells that bind to the antibody (e.g., a monoclonal antibody) can be done by Magnetic Activated Cell Sorting (MACS).

[0106] In some embodiments of the disclosed methods, sorting or separating gene signature-positive cells from gene signature-negative cells can be achieved using Magnetic-Activated Cell Sorting (MACS). Magnetic-activated cell sorting is a method for separation of various cell populations depending on their surface antigens (CD molecules) by usingsuperparamagnetic nanoparticles and columns. MACS can be used to obtain a very pure donor cell population. Engineered immune cells from engineered immune cell populations or donor cells from a donor cell population in a single-cell suspension can be magnetically labeled with microbeads. The sample is applied to a column composed of a ferromagnetic material, which is covered with a coating not disruptive to cells, thus allowing fast and gentle separation of cells. The unlabeled cells pass through the column while the magnetically labeled cells are retained within the column. The flow-through can be collected as the unlabeled cell fraction. After a washing step, the column is removed from the separator, and the magnetically labeled cells are eluted from the column.

[0107] In some embodiments of the disclosed methods, sorting or separating gene signature-positive cells from gene signature-negative cells can be achieved using acoustic wave separation in lieu of magnetic-based separation methods. While not wishing to be bound by theory, it is understood that acoustic wave separation relies on a three-dimensional standing wave to separate components of a mixture. In the context of the disclosed methods, an anti-cell surface protein antibody, such as an antibody with specificity to one or more of the cell surface proteins of the gene signatures disclosed in Tables 1-18, can be conjugated to a surface, such as an acoustic wave particle. An acoustic wave particle can be a bead. In an embodiment, engineered immune cells from an engineered immune cell population or donor cells from a donor cell population are exposed to acoustic wave particles bearing one or more anti-cell surface protein antibodies associating the acoustic wave particle with any cells expressing the target of interest. The cells are then placed in an acoustic chamber and exposed to an acoustic wave. Given the different properties of the bead-associated cells and cells that were not labeled with the antibody -bead particles, the acoustic wave separates the labeled and unlabeled cells, which can be collected while labeled cells (e.g., gene signature-positive cells) can be diverted away from the unlabeled cells.

[0108] In some embodiments, the cells are analyzed for other surface markers indicative of different cell types in a population of cells, for example, effector cells, effector memory cells, central memory cells, stem central memory' cells, etc. based on well-accepted specific surface markers for each cell ty pe. In a further aspect, provided herein are methods of detecting surface markers indicative of other attributes of engineered immune cells from an engineered immune cell population or donor cells from a donor cell population. In some embodiments, the engineered immune cells from an engineered immune cell population or donor cells from a donor cell population are analyzed for additional surface markers, thelevels of which may indicate the potency or functionality of the cells. The analysis can be qualitative or quantitative.

[0109] In some embodiments, the similar phenotype is characterized by one or more surface markers selected from CD57, CD45RO, CD45RA, CD27, CD73 and combinations thereof, optionally together with one or more RNA or protein markers from the 52-gene signature (Table 1), the 16-gene signature (Table 2) or subsets thereof (see FIG. 6B).Cytokine profiling

[0110] In one aspect, the present disclosure provides methods and reagents to analyze cytokine secretion profdes of cells from cell populations (e.g., engineered cells from an engineered cell population and / or donor cells from a donor cell population). Measuring secreted proteins, such as cytokines, from the cells of the cell population can provide information on cell attributes that may contribute to and / or correlate to an effect on the in vitro functionality of modified or engineered cells, e.g., CAR T cells, derived from donor cells. Flow cytometry methods, as described herein, can be used to generate secreted protein profiles, e.g., cytokine secretion profiles, on a single cell level. For example, a standard “cytokine secretion assay” (CSA) can be used to provide a cytokine secretion profile where a secreted cytokine of interest is characterized through the use of cell surface labeling agents specific to a component of cells from a cell population. For example, a bifunctional antibody, e.g., bispecific for a cell surface marker and a cytokine, may be used to stain cells and “catch” secreted cytokines at the cell surface. The cells may then be stained with a fluorescently labeled antibody specific to the caught cytokine. The stained cells are subsequently analyzed using fluorescent-activated cell sorting (FACS) to detect the cytokines on a single cell level.

[0111] Single-cell functional phenotypes, such as secretome profiles, e g., cytokine secretion profiles, may be generated using discrete fluidic chambers and multiplexed enzyme-linked immunosorbent assay (ELISA) cytokine capture reagents, e.g., IsoCode chip using the IsoLight System (Isoplexis). In one aspect, the present disclosure provides methods for generating cytokine secretion profiles from cells of a cell population (e.g., engineered cells of an engineered cell population and / or donor cells of a donor cell population). In one embodiment, the method comprises partitioning of cells from a cell population onto an array of separate chambers (e.g., wells, troughs, cavities, depressions, channels, etc.), wherein a chamber (from the array of chambers) comprises one or more primary cytokine binding agents, e.g., primary antibodies specific for different cytokines, for capture of cytokines secreted from cells, e.g., engineered cells from an engineered cell population and / or donorcells from a donor cell population. In other embodiments, the chamber(s) is / are configured to hold a single cell(s). Optionally, the method comprises contacting the cells with an activation agent prior to partitioning. In one embodiment, the one or more primary' cytokine binding agents are disposed or positioned on a surface (e.g., a planar surface) of the chamber and are configured to capture cytokines secreted from a cell that is within the chamber. In another embodiment, the method comprises subjecting a partition, e.g., a chamber, comprising a cell to conditions that allow one or more primary' cytokine binding agents to bind to cytokines secreted from the cell. In other embodiments, the method further comprises removing the cells from the chamber while retaining one or more secreted cytokines bound to the one or more primary' cytokine binding agents disposed on the surface. The method may further comprise contacting the bound secreted cytokines with one or more secondary cytokine binding agents, e.g., secondary antibodies specific for the one or more bound secreted cytokines, under conditions sufficient to allow the one or more secondary cytokine binding agents to bind the bound secreted cytokine. In other embodiments, the one or more secondary cytokine binding agents comprise one or more labels (as further described herein in the context of labeling agents). Such labels may be used to detect binding events, e.g., binding of a fluorescently labelled secondary cytokine binding agent to a bound secreted cytokine in the chamber, thereby providing a cytokine secretion profile for cells from a cell population. Additional details for methods and compositions are provided in Paczkowski et al. WO / 2016 / 090148, which is incorporated herein by reference in its entirety7. Cytokine secretion profiles may be expressed as a polyfunctionality index (PSI).

[0112] In another embodiment, the engineered immune cell population described herein is characterized by increased cytokine secretion. In another embodiment, the engineered immune cell population described herein is characterized by increased chemokine secretion. In some embodiments, the engineered immune cell population described herein is characterized by decreased cytokine secretion. In some embodiments, the engineered immune cell population described herein is characterized by decreased chemokine secretion. In another embodiment, the donor cell population described herein is characterized by increased cytokine secretion. In another embodiment, the donor cell population described herein is characterized by increased chemokine secretion. In some embodiments, the donor cell population described herein is characterized by decreased cytokine secretion. In some embodiments, the donor cell population described herein is characterized by' decreased chemokine secretion. Cytokine secretion can be measured by polyfunctional index score(PSI) as described in Example 6. In one embodiment, the engineered immune cell population expressing the 52 or 16 gene signature exhibit increased cytokine secretion as shown by increased PSI relative to engineered immune cell populations that do not express the 52 or 16 gene signature. In some embodiments, the PSI can be measured for the engineered immune cell population or a subpopulation thereof. In one embodiment, the subpopulation is a CD4+ subpopulation or a CD8+ subpopulation from the engineered immune cell population.

[0113] Secreted cytokines may also be captured and detected at a single cell level using next generation sequencing techniques. Briefly, cells of a cell population (e.g., engineered cells of an engineered cell population and / or donor cells of a donor cell population) are contacted with a labeling agent that is conjugated to a reporter nucleic acid molecule to provide a labelled cell (e.g., labelled engineered and / or cell labelled donor cell). In one embodiment, the labeling agent is capable of labeling (e.g., binding to) a secreted cytokine. The reporter nucleic acid molecule comprises a reporter sequence that corresponds to the labeling agent (e.g., identifies the labeling agent and / or the cellular component that the labeling agent specifically labels, such as an antibody that specifically labels or binds a cytokine). In one embodiment, the labelled cell comprises a complex coupled to a surface of the cell. In another embodiment, the complex comprises a capture agent, a secreted cytokine, and the labeling agent. In one embodiment, the capture agent is configured to bind to both a cell surface protein of the cell and the secreted cytokine. In an additional embodiment, the labelled cell comprises (i) the capture agent bound to a cell surface protein and the secreted cytokine, and (ii) the labeling agent bound to the secreted cytokine. In another embodiment, the cells are contacted with the capture agent prior to contacting with the labeling agent, and optionally the cells are contacted with an activation agent, e.g., an immune cell activation agent, prior to contacting with the capture agent and / or labeling agent. Additional details for methods and compositions are provided in McDermott et al. WO / 2021 / 072314, which is incorporated herein by reference in its entirety.

[0114] The cell populations described herein (e.g., engineered cell populations and / or donor cell populations) can be analyzed for secretion of various cytokines including, without limitation, one or more of granzyme B, IFN-gamma, MIP-1 alpha, perforin, TNF-alpha, TNF-Determination of in vitro functionality of CAR T cells

[0115] In this further aspect, the instant disclosure provides a method for analyzing and / or determining in vitro functionality (including one or more of potency, i.e., cytotoxicity, cell fitness, and / or polyfunctionality, i.e., cytokine secretion profiling) of an engineered cell derived from a donor cell of a donor cell population. In some embodiments, the donor cell is an immune cell. In other embodiments, the engineered cell is an engineered immune cell, for example, a CAR T cell. Currently, there are different methods for evaluating the in vitro functionality of CAR T products. Upon exposing / binding to target cells, CAR T cells exert cytotoxicity partly through secretion of one or more effector cytokines. Effective cytokine induction can be used as an indication for potency or poly functionality of CAR T cells. Secreted cytokine can be measured by an immune assay such as ELISA. Cytokine induction of CAR T cells can also be assessed by intracellular staining after fixation of cells.

[0116] Potency, as used herein, can refer to the ability of one or more immune cells, such as CAR T cells derived from donor cells of a donor cell population, to kill a target cell, such as an antigen positive tumor cell.

[0117] Polyfunctionality, as used herein, can refer to the ability of one or more immune cells, such as CAR T cells derived from donor cells of a donor cell population, to secrete more than one effector cytokine or molecule upon target or antigen activation. In some embodiments, polyfunctional CAR T cells secrete two or more effector cytokines, or three or more effector cytokines, upon target or antigen activation.

[0118] In one aspect of the instant disclosure, cell populations can be contacted with or exposed to an activation agent at one or more time points during the process of manufacturing engineered cells from donor cells, as described herein.

[0119] In some embodiments, the CAR T cells are allogeneic CAR T cells. In some embodiments, the CAR T cells are TCR- allogeneic CAR T cells. In contrast to TCR+ CAR T cells, in the absence of a functional TCR, the activation of the engineered T cells relies on the interaction of the CAR with the antigen.

[0120] The instant disclosure also provides an overall process for screening, characterizing and analyzing cell populations, such as donor cells from a donor cell population and / or engineered cell populations, e.g., CAR T cells, derived from such donor cells. Accordingly, in one aspect, the instant disclosure provides a method for analyzing a population of donor cells, such as donor immune cells, or engineered donor cells, such as engineered donor immune cells, for example, allogeneic CAR T cells, comprising steps ofmeasuring or determining a percentage or amount of T cells that express the one or more of the gene signature disclosed herein in the population of cells, and determining in vitro functionality of the population of cells.

[0121] In some embodiments, the method further comprises the step of measuring a percentage or amount of CAR+ T cells. In some embodiments, the percentage or amount of CAR+ T cells can be determined by using a reagent, for example, an anti-id antibody or an antigen. The antigen can be soluble or immobilized on a solid surface. The reagent can be directly labeled for detection or bound by a secondary labeled reagent for detection. In some embodiments, the method further comprises the step of measuring or detecting CD52+ cells. In some embodiments, the CAR T cells are manufactured in a GMP manufacturing process. In some embodiments, the population of engineered immune cells are TCR- allogeneic CAR T cells manufactured in a GMP manufacturing process. In some embodiments, the population of engineered immune cells are GMP allogeneic CAR T drug substance or drug product.

[0122] In certain embodiments, the CAR T cells are specific for EGFRvIII, WT-1, CD20, CD23, CD30, CD38, CD33, CD133, MHC-WT1, TSPAN10, MHC-PRAME, Livl, ADAM10, CHRNA2, LeY, NKGD2D, CS1, CD44v6, ROR1, Claudin-18.2, Mucl7, FAP alpha. Ly6G6D, c6orf23. G6D, MEGT1, NG25. CD19, BCMA, FLT3, CD70, DLL3, CD52 or CD34. In certain embodiments, the CAR T cells are EGFRvIII CAR T cells, CD 19 CAR T cells, CD20 CAR T cells, CD33 CAR T cells, ROR1 CAR T cells, CD70 CAR T cells, FLT3 CAR T cells, BCMA CAR T cells, or DLL3 CAR T cells. In certain embodiments, the CAR T cells are BCMA CAR T cells. In certain embodiments, the CAR T cells are CD 19 CAR T cells. In certain embodiments, the CAR T cells are CD70 CAR T cells.Immune Cells

[0123] Engineered cells derived from the donor cells or donor cells derived from a donor cell population are suitable for use with the methods and / or reagents described herein.

[0124] Prior to the in vitro manipulation or genetic modification (e.g., as described herein), donor cells for use in methods described herein (e.g., immune cells) can be obtained from a subject. Donor cells can be obtained from a number of non-limiting sources, including peripheral blood mononuclear cells, bone marrow, lymph node tissue, cord blood, thymus tissue, stem cell- or iPSC-derived immune cells, tissue from a site of infection, ascites, pleural effusion, spleen tissue, and tumors. In some embodiments, any number of T cell lines available and known to those skilled in the art, can be used. In some embodiments, donor cells can be derived from a healthy donor, from a patient diagnosed with cancer or from apatient diagnosed with an infection. In some embodiments, donor cells can be part of a mixed population of cells which present different phenotypic characteristics.

[0125] In some embodiments, immune cells are allogeneic immune cells obtained from a donor, who is a different individual from the subject who will receive the engineered immune cells.

[0126] In some embodiments, immune cells comprise T cells. T cells can be obtained from a number of sources, including peripheral blood mononuclear cells (PBMCs), bone marrow, lymph nodes tissue, cord blood, thymus tissue, stem cell- or iPSC-derived T cells, tissue from a site of infection, ascites, pleural effusion, spleen tissue, and tumors. In certain some embodiments, T cells can be obtained from a volume of blood collected from the subject using any number of techniques known to the skilled person, such as FICOLL™ separation.

[0127] Donor cells can be obtained from the circulating blood of an individual by apheresis. The apheresis product typically contains lymphocytes, including T cells, monocytes, granulocytes, B cells, other nucleated white blood cells, red blood cells, and platelets. In some embodiments, the cells collected by apheresis can be washed to remove the plasma fraction and placed in an appropriate buffer or media for subsequent processing.

[0128] Donor PBMCs can be used directly for genetic modification with the immune cells (such as CARs or TCRs) using methods as described herein. In certain embodiments, after isolating the PBMCs, T lymphocytes can be further isolated and both cytotoxic and helper T lymphocytes can be sorted into naive, memory, and effector T cell subpopulations either before or after genetic modification and / or expansion.

[0129] In certain embodiments, T cells are isolated from PBMCs by lysing the red blood cells and depleting the monocytes, for example, using centrifugation through a PERCOLL™ gradient. A specific subpopulation of T cells, such as CCR7+, CD95+, CD122, CD27+, CD69+, CD127+, CD28+, CD3+, CD4+, CD8+, CD25+, CD62L+, CD45RA+, and CD45RO+ T cells can be further isolated by positive or negative selection techniques known in the art. For example, enrichment of a T cell population by negative selection can be accomplished with a combination of antibodies directed to surface markers unique to the negatively selected cells. One method for use herein is cell sorting and / or selection via negative magnetic immunoadherence or flow cytometry that uses a cocktail of monoclonal antibodies directed to cell surface markers present on the cells negatively selected. For example, to enrich for CD4+cells by negative selection, a monoclonal antibody cocktail typically includes antibodies to CD14, CD20, CDllb, CD16, HLA-DR, and CD8. Flowcytometry and cell sorting can also be used to isolate cell populations of interest for use in the present disclosure.

[0130] In some embodiments, a population of donor cells, e.g., immune cells such as T cells, is enriched for CD4+ cells.

[0131] In some embodiments, a population of donor cells, e.g., immune cells such as T cells, is enriched for CD8+ cells.

[0132] In some embodiments, CD8+ cells are further sorted into naive, central memoiy. and effector cells by identifying cell surface antigens that are associated with each of these types of cells. In some embodiments the expression of phenotypic markers for naive T cells include CD45RA+, CD95-, IL2RD-, CCR7+, and CD62L+. In some embodiments the expression of phenotypic markers for stem cell memory T cells include CD45RA+, CD95+, IL2RD □, CCR7+, and CD62L+. In some embodiments the expression of phenotypic markers for central memory T cells include CD45RO+, CD95+. IL2RC C, CCR7+, and CD62L+. In some embodiments the expression of phenotypic markers for effector memory T cells include CD45RO+, CD95+, IL2RD D, CCR7-, and CD62L-. In some embodiments the expression of phenotypic markers for T effector cells include CD45RA+, CD95+, IL2RD □. CCR7-, and CD62L-. Thus, CD4+ and / or CD8+ T helper cells can be sorted into naive, stem cell memory, central memory, effector memoiy' and T effector cells by identifying cell populations that have cell surface antigens.

[0133] It will be appreciated that donor PBMCs can further include other cytotoxic lymphocytes such as NK cells or NKT cells. An expression vector carrying the coding sequence of a chimeric receptor as disclosed herein can be introduced into a population of human donor T cells, NK cells or NKT cells. Standard procedures are used for cryopreservation of T cells expressing the CAR for storage and / or preparation for use in a human subject. In one embodiment, the in vitro transduction, culture and / or expansion of T cells are performed in the absence of non-human animal derived products such as fetal calf serum and fetal bovine serum. In various embodiments a cryopreservative media can comprise, for example, CryoStor® CS2, CS5, or CS10 or other medium comprising DMSO, or a medium that does not comprise DMSO.Engineered Immune Cells

[0134] Provided herein are engineered immune cells expressing the CARs of the disclosure (e.g., CAR T cells) that have been derived from donor cells as described herein. In one embodiment, the engineered immune cells are (i) derived from donor cells of a donor cellpopulation having one or more of the gene signatures as described herein and (ii) characterized by preferential expansion in vivo as compared to an engineered immune cell derived from donor cells that lack one or more of the gene signatures as described herein.

[0135] In some embodiments, an engineered immune cell comprises a population of CARs, each CAR comprising extracellular antigen-binding domains. In some embodiments, an engineered immune cell comprises a population of CARs, each CAR comprising different extracellular antigen-binding domains. In some embodiments, an immune cell comprises a population of CARs, each CAR comprising the same extracellular antigen-binding domains.

[0136] The engineered immune cells can be allogeneic.

[0137] In some embodiments, the engineered immune cell is a T cell (e.g., inflammatory T-lymphocyte cytotoxic T-lymphocyte, regulatory' T-lymphocyte, helper T-lymphocyte, central memory T cell (Tern), effector memory T cell (Tern), tumor infiltrating lymphocyte (TIL)). NK cell, NK-T-celL TCR-expressing cell, dendritic cell, killer dendritic cell, a mast cell, or a B-cell.

[0138] In one embodiment, the engineered immune cell can be derived from a donor cell with a gene signature as described herein. In some embodiments, the engineered immune cell can be derived from the group consisting of CD4+ T-lymphocytes and CD8+ T-lymphocytes. In some embodiments, the engineered immune cell is a T cell. In some embodiments, the engineered immune cell is a memory T cell. In some embodiments, the engineered immune cell is a central memory' T cell. In some embodiments, the engineered immune cell is an effector memory T cells. In some embodiments, the donor cells are obtained or prepared from peripheral blood. In some embodiments, the donor cells are obtained or prepared from peripheral blood mononuclear cells (PBMCs). In some embodiments, the donor cells are obtained or prepared from bone marrow. In some embodiments, the donor cells are obtained or prepared from umbilical cord blood. In some embodiments, the donor cells are human cells. In some embodiments, the donor cells are transfected or transduced by the nucleic acid vector using a method selected from the group consisting of electroporation, sonoporation, biolistics (e.g., Gene Gun), transfection, lipid transfection, polymer transfection, nanoparticles, viral transduction or viral transfection (e.g., retrovirus, lentivirus, AAV) or polyplexes.Binding Agents (including antibodies and fragments thereof)

[0139] As used herein, the term “antibody” refers to a polypeptide that includes canonical immunoglobulin sequence elements sufficient to confer specific binding to aparticular target antigen. As is known in the art, intact antibodies as produced in nature are approximately 150 kD tetrameric agents comprised of two identical heavy chain polypeptides (about 50 kD each) and two identical light chain polypeptides (about 25 kD each) that associate with each other into what is commonly referred to as a " Y-shaped" structure. Each heavy chain is comprised of at least four domains (each about 110 amino acids long)- an amino-terminal variable (VH) domain (located at the tips of the Y structure), followed by three constant domains: CHI, CH2, and the carboxy -terminal CH3 (located at the base of the Y's stem). A short region, known as the “switch”, connects the heavy chain variable and constant regions. The "hinge" connects CH2 and CH3 domains to the rest of the antibody. Two disulfide bonds in this hinge region connect the two heavy chain polypeptides to one another in an intact antibody. Each light chain is comprised of two domains - an aminoterminal variable (VL) domain, followed by a carboxy -terminal constant (CL) domain. Those skilled in the art are well familiar with antibody structure and sequence elements, recognize “variable” and “constant” regions in provided sequences, and understand that there may be some flexibility in definition of a "boundary" between such domains such that different presentations of the same antibody chain sequence may, for example, indicate such a boundary at a location that is shifted one or a few residues relative to a different presentation of the same antibody chain sequence.

[0140] Intact antibody tetramers are comprised of tw o heavy chain-light chain dimers in which the heavy and light chains are linked to one another by a single disulfide bond; two other disulfide bonds connect the heavy chain hinge regions to one another, so that the dimers are connected to one another and the tetramer is formed. Naturally produced antibodies are also glycosylated, typically on the CH2 domain. Each domain in a natural antibody has a structure characterized by an “immunoglobulin fold” formed from two beta sheets (e.g., 3-, 4-, or 5- stranded sheets) packed against each other in a compressed antiparallel beta barrel. Each variable domain contains three hypervariable loops known as “complement determining regions” (CDR1, CDR2, and CDR3) and four somewhat invariant "framew ork" regions (FRL FR2, FR3, and FR4). When natural antibodies fold, the FR regions form the beta sheets that provide the structural framew ork for the domains, and the CDR loop regions from both the heavy and light chains are brought together in three-dimensional space so that they create a single hypervariable antigen binding site located at the tip of the Y structure. The Fc region of naturally occurring antibodies binds to elements of the complement system, and also to receptors on effector cells, including for example effector cells that mediate cytotoxicity. Asis known in the art, affinity and / or other binding attributes of Fc regions for Fc receptors can be modulated through glycosylation or other modification. In some embodiments, antibodies produced and / or utilized in accordance with the present invention include glycosylated Fc domains, including Fc domains with modified or engineered such glycosylation.

[0141] For purposes of the instant disclosure, in certain embodiments, any polypeptide or complex of polypeptides that includes sufficient immunoglobulin domain sequences as found in natural antibodies can be referred to and / or used as an “antibody,” whether such polypeptide is naturally produced (e.g., generated by an organism reacting to an antigen), or produced by recombinant engineering, chemical synthesis, or other artificial system or methodology. In some embodiments, an antibody is polyclonal; in some embodiments, an antibody is monoclonal. In some embodiments, an antibody has constant region sequences that are characteristic of mouse, rabbit, primate, or human antibodies. In some embodiments, antibody sequence elements are humanized, primatized. chimeric, etc., as is known in the art.

[0142] Moreover, the term “antibody” as used herein, can refer to any of the art-known or developed constructs or formats for utilizing antibody structural and functional features in alternative presentation. For example, in some embodiments, an antibody utilized in the methods of the instant disclosure is in a format selected from, but not limited to, intact IgA, IgG, IgE or IgM antibodies; bi- or multi- specific antibodies (e.g., Zybodies®, etc.); antibody fragments such as Fab fragments, Fab fragments, F(ab)2 fragments, Fd fragments, and isolated CDRs or sets thereof; single chain variable fragments (scFVs); polypeptide-Fc fusions; single domain antibodies (e.g., shark single domain antibodies such as IgNAR or fragments thereof); camelid antibodies (also referred to herein as nanobodies or VHHs); shark antibodies, masked antibodies (e.g., Probodies®); Small Modular ImmunoPharmaceuticals (SMIPs™ ); single chain or Tandem diabodies (TandAb®); VHHs; Anticalins®; Nanobodies® minibodies; BiTE®s; ankyrin repeat proteins or DARPINs®; Avimers®; DARTs; TCR-like antibodies;, Adnectins®; Affilins®; Trans-bodies®; Affibodies®; TrimerX®; MicroProteins; Fynomers®, Centyrins®; and KALBITOR®s. In some embodiments, an antibody may lack a covalent modification (e.g., attachment of a glycan) that it would have if produced naturally. In some embodiments, an antibody may contain a covalent modification (e.g., attachment of a glycan, a payload (e.g., a detectable moiety, a therapeutic moiety, a catalytic moiety, etc.), or other pendant group (e.g., poly-ethylene glycol, etc.).

[0143] As used herein, the term “antibody agent” generally refers to an agent that specifically binds to a particular antigen. In some embodiments, the term encompasses any polypeptide or polypeptide complex that includes immunoglobulin structural elements sufficient to confer specific binding. Exemplary antibody agents include but are not limited to monoclonal antibodies or polyclonal antibodies. In some embodiments, an antibody agent may include one or more constant region sequences that are characteristic of mouse, rabbit, primate, or human antibodies. In some embodiments, an antibody agent may include one or more sequence elements are humanized, primatized, chimeric, etc. as is know n in the art. In many embodiments, the term “antibody agent” is used to refer to one or more of the art-known or developed constructs or formats for utilizing antibody structural and functional features in alternative presentation. For example, an antibody agent utilized in accordance with the present invention is in a format selected from, but not limited to, intact IgA, IgG, IgE or IgM antibodies; bi- or multi- specific antibodies (e.g., Zybodies®, etc.); antibody fragments such as Fab fragments. Fab’ fragments, F(ab’)2 fragments, Fd fragments, and isolated CDRs or sets thereof; single chain Fvs; polypeptide-Fc fusions; single domain antibodies (e.g., shark single domain antibodies such as IgNAR or fragments thereof); cameloid antibodies; masked antibodies (e.g., Probodies®); Small Modular ImmunoPharmaceuticals (SMIPs™ ); single chain or Tandem diabodies (TandAb®); VHHs; Anticalins®; Nanobodies® minibodies; BiTE®s; ankyrin repeat proteins or DARPINs®; Avimers®; DARTs; TCR-like antibodies; Adnectins®; Affilins®; Trans-bodies®; Affibodies®; TrimerX®; MicroProteins; Fynomers®, Centyrins®; and KALBITOR®s.

[0144] An antibody or antibody agent used in performing the methods of the instant disclosure can be single chained or double chained. In some embodiments, the antibody or antigen binding molecule is single chained. In certain embodiments, the antigen binding molecule is selected from the group consisting of an scFv, a Fab, a Fab', a Fv, a F(ab’)2, a dAb, and any combination thereof.

[0145] Antibodies and antibody agents include antibody fragments. An antibody fragment comprises a portion of an intact antibody, such as the antigen binding or variable region of the intact antibody. Antibody fragments include, but are not limited to, Fab, Fab’, Fab’-SH, F(ab’)2, Fv, diabody, linear antibodies, multispecific formed from antibody fragments antibodies and scFv fragments, and other fragments. Antibodies also include, but are not limited to, polyclonal monoclonal, chimeric dAb (domain antibody), single chain, Fab, Fa, F(ab’)2 fragments, and scFvs. An antibody can be a whole antibody, orimmunoglobulin, or an antibody fragment. Antibody fragments can be made by various techniques, including but not limited to proteolytic digestion of an intact antibody as well as production by recombinant host cells (e.g., E. coli, Chinese Hamster Ovary (CHO) cells, or phage), as known in the art.

[0146] In some embodiments, an antibody or antibody agent can be a chimeric antibody (see, e.g., U. S. Pat. No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984)). A chimeric antibody can be an antibody in which a portion of the heavy and / or light chain is derived from a particular source or species, while the remainder of the heavy and / or light chain is derived from a different source or species. In one example, a chimeric antibody can comprise anon-human variable region (e g., a variable region derived from a mouse, rat, hamster, rabbit, or non-human primate, such as a monkey) and a human constant region. In a further example, a chimeric antibody can be a “class switched’' antibody in which the class or subclass has been changed from that of the parent antibody. Chimeric antibodies include antigen-binding fragments thereof.

[0147] In some embodiments, a chimeric antibody can be a humanized antibody (See, e.g., Almagro and Fransson, Front. Biosci., 13:1619-1633 (2008); Riechmann et al., Nature, 332:323-329 (1988); Queen et al., Proc. Natl Acad. Sci. USA 86:10029-10033 (1989): U. S. Pat. Nos. 5,821,337, 7,527,791, 6,982,321, and 7,087,409; Kashmin et al., Methods 36:25-34 (2005); Padlan, Mol. Immunol, 28:489-498 (1991); Dall'Acqua et al., Methods, 36:43-60 (2005); Osbourn et al., Methods, 36:61-68 (2005); and Klimka et al., Br. J. Cancer, 83:252-260 (2000)). A humanized antibody is a chimeric antibody comprising amino acid residues from non-human hypervariable regions and amino acid residues from human FRs. In certain embodiments, a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable regions (e.g., CDRs) correspond to those of a non-human antibody, and all or substantially all of the Framework Regions (FRs) correspond to those of a human antibody. A humanized antibody optionally can comprise at least a portion of an antibody constant region derived from a human antibody.

[0148] In some embodiments, an antibody or antibody agent provided herein is a human antibody. Human antibodies can be produced using various techniques known in the art (See, e.g., van Dijk and van de Winkel, Curr. Opin. Pharmacol, 5: 368-74 (2001); and Lonberg, Curr. Opin. Immunol, 20:450-459 (2008)). A human antibody can be one which possesses an amino acid sequence which corresponds to that of an antibody produced by ahuman or a human cell or derived from a non-human source that utilizes human antibody repertoires or other human antibody-encoding sequences. This definition of a human antibody specifically excludes a humanized antibody comprising non-human antigen-binding residues. Human antibodies may be prepared using methods well known in the art.Chimeric Antigen Receptors

[0149] As used herein, chimeric antigen receptors (CARs) are proteins that specifically recognize target antigens (e.g., target antigens on cancer cells). When bound to the target antigen, the CAR can activate the immune cell to attack and destroy the cell bearing that antigen (e.g., the cancer cell). CARs can also incorporate costimulatory or signaling domains to increase their potency. See Krause et al., J. Exp. Med., Volume 188, No. 4, 1998 (619-626); Finney et al., Journal of Immunology, 1998, 161: 2791-2797, Song et al., Blood 119:696-706 (2012); Kalos etal., Set. Transl. Med. 3:95 (2011); Porter et al., N. Engl. J. Med.365:725-33 (2011). and Gross et al., Annu. Rev. Pharmacol. Toxicol. 56:59-83 (2016)1 U. S. Patent Nos. 7,741,465, and 6,319,494.

[0150] Chimeric antigen receptors described herein comprise an extracellular domain, a transmembrane domain, and an intracellular domain, wherein the extracellular domain comprises an antigen binding domain that specifically binds to the target.

[0151] In some embodiments, antigen-specific CARs further comprise a safety switch and / or one or more monoclonal antibody specific-epitope.i. Antigen Binding Domains

[0152] As discussed above, CARs described herein comprise an antigen binding domain. An "‘antigen binding domain7' as used herein means any polypeptide that binds a specified target antigen. In some embodiments, the antigen binding domain binds to an antigen on a tumor cell. In some embodiments, the antigen binding domain binds to an antigen on a cell involved in a hyperproliferative disease.

[0153] In some embodiments, the antigen binding domain comprises a variable heavy chain, variable light chain, and / or one or more CDRs described herein. In some embodiments, the antigen binding domain is a single chain variable fragment (scFv), comprising light chain CDRs CDR1, CDR2 and CDR3, and heavy chain CDRs CDR1, CDR2 and CDR3.

[0154] An antigen binding domain is said to be “selective” when it binds to one target more tightly or with higher affinity than it binds to a second target.

[0155] The antigen binding domain of the CAR may selectively target a cancer antigen. In some embodiments, the cancer antigen is selected from EGFRvIII, WT-1, CD20,CD23, CD30, CD38, CD33, CD 133, MHC-WT1, TSPAN10, MHC-PRAME, Livl, ADAM10, CHRNA2, LeY, NKGD2D, CS1, CD44v6, ROR1, Claudin-18.2, Mucl7, FAP alpha, Ly6G6D, c6orf23, G6D, MEGT1, NG25, CD19, BCMA, FLT3, CD70, DLL3, CD52 or CD34. In some embodiments, the CAR comprises an antigen binding domain that targets EGFRvIII, WT-1, CD20, CD23, CD30, CD38, CD33, CD133, MHC-WT1, TSPAN10, MHC-PRAME, Livl, ADAM10, CHRNA2, LeY, NKGD2D, CS1, CD44v6, ROR1, Claudin-18.2, Mucl7, FAP alpha, Ly6G6D, c6orf23, G6D, MEGT1, NG25, CD19, BCMA, FLT3, CD70, DLL3, CD52 or CD34.

[0156] In some embodiments, the cancer antigen is selected from the group consisting of carbonic anhydrase IX (CAIX), carcinoembryonic antigen (CEA), CDS, CD7, CDIO, CD19, CD20, CD22, CD30, CD33, CD34, CD38, CD41, CD44, CD49f, CD56, CD74, CD123, CD133, CD138, an antigen of a cytomegalovirus (CMV) infected cell (e g., a cell surface antigen), epithelial glycoprotein (EGP 2), epithelial glycoprotein-40 (EGP-40), epithelial cell adhesion molecule (EpCAM), receptor tyrosine-protein kinases erb- B2,3,4, folate-binding protein (FBP), fetal acetylcholine receptor (AchR), folate receptors, Ganglioside G2 (GD2), Ganglioside G3 (GD3), human Epidermal Grow th Factor Receptor 2 (HER-2), human telomerase reverse transcriptase (hTERT), Interleukin- 13 receptor subunit alpha-2 (IL-13Ra2), K-light chain, kinase insert domain receptor (KDR), Lewis A (CA19.9),, LI cell adhesion molecule (LICAM), melanoma antigen family A, 1 (MAGE-AI), Mucin 16 (Muc-16), Mucin 1 (Muc-1), Mesothelin (MSLN), NKG2D ligands, cancer-testis antigen NY-ESO-1, oncofetal antigen (h5T4), prostate stem cell antigen (PSCA), prostate-specific membrane antigen (PSMA), tumor- associated glycoprotein 72 (TAG-72), vascular endothelial growth factor R2 (VEGF- R2), and Wilms tumor protein (WT-1).

[0157] In certain some embodiments, the polypeptide structure of the antigen binding domains is based on antibodies, including, but not limited to, monoclonal antibodies, bispecific antibodies, minibodies, domain antibodies, synthetic antibodies (sometimes referred to herein as "antibody mimetics”), chimeric antibodies, humanized antibodies, human antibodies, antibody fusions (sometimes referred to herein as “antibody conjugates”), and fragments thereof, respectively. In some embodiments, the antigen binding domain comprises or consists of avimers.

[0158] In some embodiments, an antigen binding domain is a scFv.

[0159] In some embodiments, an antigen-selective CAR comprises a leader or signal peptide.

[0160] In some embodiments, a CAR-immune cell (e.g., CAR T cell) which can form a component of an engineered immune cell population (derived from donor cells of a donor cell population as described herein) generated by practicing the methods of the instant disclosure comprises a polynucleotide encoding a safety switch polypeptide, such as for example RQR8. See, e.g., WO2013153391 A, which is hereby incorporated by reference in its entirety. In a CAR-immune cell (e.g., a CAR T cell) comprising the polynucleotide, the safety switch polypeptide can be expressed at the surface of a CAR-immune cell (e.g., CAR T cell).ii. Hinge Domain

[0161] The extracellular domain of the CARs of the disclosure can comprise a ‘’hinge” domain (or hinge region). The term generally refers to any polypeptide that functions to link the transmembrane domain in a CAR to the extracellular antigen binding domain in a CAR. In particular, hinge domains can be used to provide more flexibility and accessibility for the extracellular antigen binding domain.

[0162] A hinge domain can comprise up to 300 amino acids — in some embodiments 10 to 100 amino acids or in some embodiments 25 to 50 amino acids. The hinge domain can be derived from all or part of naturally occurring molecules, such as from all or part of the extracellular region of CD8, CD4, CD28, 4-1 BB, or IgG (in particular, the hinge region of an IgG; it will be appreciated that the hinge region can contain some or all of a member of the immunoglobulin family such as IgGl, IgG2, IgG3, IgG4, IgA, IgD, IgE, IgM, or fragment thereof), or from all or part of an antibody heavy-chain constant region. Alternatively, the hinge domain can be a synthetic sequence that corresponds to a naturally occurring hinge sequence or can be an entirely synthetic hinge sequence. In some embodiments said hinge domain is a part of human CD8a chain (e.g., NP_001139345.1). In other embodiments, said hinge and transmembrane domains comprise a part of human CD8a chain. In some embodiments, the hinge domain of CARs described herein comprises a subsequence of CD8a, an IgGl, IgG4, PD-1 or an FcyRIIIa, in particular the hinge region of any of an CD8a, an IgGl, IgG4, PD-1 or an FcyRIIIa. In some embodiments, the hinge domain comprises a human CD8a hinge, a human IgGl hinge, a human IgG4, a human PD-1 or a human FcyRIIIa hinge. In some embodiments the CARs disclosed herein comprise a scFv, CD8a human hinge and transmembrane domains, the CD3^ signaling domain, and 4- IBB signaling domain.iii. Transmembrane Domain

[0163] The CARs of the disclosure are designed with a transmembrane domain that is fused to the extracellular domain of the CAR. It can similarly be fused to the intracellular domain of the CAR. In some instances, the transmembrane domain can be selected or modified by amino acid substitution to avoid binding of such domains to the transmembrane domains of the same or different surface membrane proteins to minimize interactions with other members of the receptor complex. In some embodiments, short linkers can form linkages between any or some of the extracellular, transmembrane, and intracellular domains of the CAR.

[0164] Suitable transmembrane domains for a CAR disclosed herein have the ability to (a) be expressed at the surface an immune cell such as, for example without limitation, a lymphocyte cell, such as a T helper (Th) cell, cytotoxic T (Tc) cell. T regulatory (Treg) cell, or Natural killer (NK) cells, and / or (b) interact with the extracellular antigen binding domain and intracellular signaling domain for directing the cellular response of an immune cell against a target cell.

[0165] The transmembrane domain can be derived either from a natural or from a synthetic source. Where the source is natural, the domain can be derived from any membrane-bound or transmembrane protein.

[0166] Transmembrane regions of particular use in this disclosure can be derived fromSLAMF6 (NTB-A, Lyl08), SLAM (SLAMF CD 150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG / Cbp, CD19a, a ligand that specifically binds with CD83, or any combination thereof.

[0167] As non-limiting examples, the transmembrane region can be derived from, or be a portion of a T cell receptor such as a, 0, y or 5, polypeptide constituting CD3 complex, IL-2 receptor p 5 (a chain), p75 (0 chain) or y chain, subunit chain of Fc receptors, in particular Fey receptor III or CD proteins. Alternatively, the transmembrane domain can be synthetic and can comprise predominantly hydrophobic residues such as leucine and valine. In some embodiments said transmembrane domain is derived from the human CD8a chain (e.g, NP_001139345.1).

[0168] In some embodiments, the transmembrane domain in the CAR of the disclosure is a CD8a transmembrane domain.

[0169] In some embodiments, the transmembrane domain in the CAR of the disclosure is a CD28 transmembrane domain.iv. Intracellular Domain

[0170] The intracellular (cytoplasmic) domain of the CARs of the disclosure can provide activation of at least one of the normal effector functions of the immune cell comprising the CAR. Effector function of a T cell, for example, can refer to cytolytic activity or helper activity, including the secretion of cytokines.

[0171] In some embodiments, an activating intracellular signaling domain for use in a CAR can be the cytoplasmic sequences of, for example without limitation, the T cell receptor and co-receptors that act in concert to initiate signal transduction following antigen receptor engagement, as well as any derivative or variant of these sequences and any synthetic sequence that has the same functional capability.

[0172] It will be appreciated that suitable (e g., activating) intracellular domains include, but are not limited to signaling domains derived from (or corresponding to) CD28, OX-40, 4-1BB / CD137, CD2, CD7, CD27, CD30, CD40, programmed death-1 (PD-1), inducible T cell costimulator (ICOS), lymphocyte function-associated antigen- 1 (LFA-1, CDl-la / CD18), CD3 gamma, CD3 delta, CD3 epsilon, CD247, CD276 (B7-H3), LIGHT, (TNFSF14), NKG2C. Ig alpha (CD79a), DAP-10. Fc gamma receptor, MHC class 1 molecule, TNF receptor proteins, an Immunoglobulin protein, cytokine receptor, integrins. Signaling Lymphocytic Activation Molecules (SLAM proteins), activating NK cell receptors, BTLA, a Toll ligand receptors, ICAM-1, B7-H3, CDS, ICAM-1, GITR, BAFFR,LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8alpha, CD8beta, IL-2R beta, IL-2R gamma, IL-7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD1 Id, ITGAE, CD 103, ITGAL, CD1 la, LFA-1, ITGAM. CD1 lb, ITGAX. CD1 1c, ITGB1, CD29,costimulatory molecules, or fragments thereof, not listed above are within the scope of the disclosure.

[0175] In some embodiments, the intracellular / cytoplasmic domain of the CAR can be designed to comprise the 4-1BB / CD137 domain by itself or combined with any other desired intracellular domain(s) useful in the context of the CAR of the disclosure. The complete native amino acid sequence of 4-1BB / CD137 is described in NCBI Reference Sequence: NP_ 001552.2. The complete native 4-1BB / CD137 nucleic acid sequence is described in NCBI Reference Sequence: NM_ 001561.5.

[0176] In some embodiments, the intracellular / cytoplasmic domain of the CAR can be designed to comprise the CD28 domain by itself or combined with any other desired intracellular domain(s) useful in the context of the CAR of the disclosure. The complete native amino acid sequence of CD28 is described in NCBI Reference Sequence: NP_006130.1. The complete native CD28 nucleic acid sequence is described in NCBI Reference Sequence: NM_006139.1.

[0177] In some embodiments, the intracellular / cytoplasmic domain of the CAR can be designed to comprise the CD3 zeta domain by itself or combined with any other desired intracellular domain(s) useful in the context of the CAR of the disclosure.

[0178] For example, the intracellular domain of the CAR can comprise a CD3 zeta chain portion and a portion of a costimulatory signaling molecule. The intracellular signaling sequences within the intracellular signaling portion of the CAR of the disclosure can be linked to each other in a random or specified order. In some embodiments, the intracellular domain is designed to comprise the activating domain of CD3 zeta and a signaling domain of CD28. In some embodiments, the intracellular domain is designed to comprise the activating domain of CD3 zeta and a signaling domain of 4- IBB.

[0179] In some embodiments the intracellular signaling domain of the CAR of the disclosure comprises a domain of a co-stimulatory molecule. In some embodiments, the intracellular signaling domain of a CAR of the disclosure comprises a part of co-stimulatory molecule selected from the group consisting of fragment of 4-1BB (GenBank: AAA53133.) and CD28 (NP_006130.1).Engineered Immune Cells Comprising CARs

[0180] Also provided herein are engineered immune cells and populations of engineered immune cells expressing CAR (e g., CAR T cells or CAR+ cells), which are derived from donor cells having a gene signature that has been detected according to themethods described herein. Such engineered immune cells may be cells that have been depleted of cells not expressing one or more gene signatures disclosed herein and / or endogenous TCR.

[0181] In some embodiments, an engineered immune cell comprises a CAR T cell, each CAR T cell comprising an extracellular antigen-binding domain and expresses one or more of the gene signatures disclosed herein

[0182] The engineered immune cells can be allogeneic.

[0183] In some embodiments, an engineered immune cell or population of engineered immune cells is a T cell (e.g.. inflammatory T-lymphocyte cytotoxic T-lymphocyte, regulatory T-lymphocyte, helper T-lymphocyte, memory T cell, central memory T cell (Tcm), effector memory T cell (Tern), tumor infdtrating lymphocyte (TIL)), NK cell, NK-T-cell, TCR-expressing cell, dendritic cell, killer dendritic cell, a mast cell, or a B-cell, and expresses a CAR. In some embodiments, the T cell can be derived from the group consisting of CD4+ T lymphocytes, CD8+ T lymphocytes or population comprising a combination of CD4+ and CD8+ T cells.

[0184] In some embodiments, an engineered immune cell or population of engineered immune cells that are generated using the disclosed methods can be derived from a stem cell. The stem cells can be adult stem cells, non-human embryonic stem cells, more particularly non-human stem cells, cord blood stem cells, progenitor cells, bone marrow stem cells, induced pluripotent stem cells, totipotent stem cells or hematopoietic stem cells.

[0185] In some embodiments, an engineered immune cell or a population of immune cells that are generated using the disclosed methods is obtained or prepared from peripheral blood, wherein the peripheral blood comprises donor cells from a donor cell population having a gene signature as described herein. In some embodiments, an engineered immune cell is obtained or prepared from peripheral blood mononuclear cells (PBMCs). In some embodiments, an engineered immune cell is obtained or prepared from bone marrow. In some embodiments, an engineered immune cell is obtained or prepared from umbilical cord blood. In some embodiments, the donor cell is a human cell. In some embodiments, the donor cell is transfected or transduced by the nucleic acid vector using a method selected from the group consisting of electroporation, sonoporation, biolistics (e.g., Gene Gun), lipid transfection, polymer transfection, nanoparticles, viral transfection (e.g., retrovirus, lentivirus, AAV) or polyplexes.

[0186] In some embodiments, the engineered immune cells expressing at their cell surface membrane an antigen-specific CAR comprise a percentage of stem cell memory and central memory cells greater than 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%.

[0187] In some embodiments, engineered immune cells expressing at their cell surface membrane an antigen-specific CAR comprise a percentage of stem cell memory and central memory cells of about 10% to about 60%, about 10% to about 50%, about 10% to about 40%, about 15% to about 50%, about 15% to about 40%, about 20% to about 60%, or about 20% to about 70%.

[0188] In some embodiments, engineered immune cells expressing at their cell surface membrane an antigen-specific CAR enriched in TCM and / or TSCM cells such that the engineered immune cells comprise at least about 60%, 65%, 70%, 75%, or 80% combined TCM and TSC cells. In some embodiments, engineered immune cells expressing at their cell surface membrane an antigen-specific CAR are enriched in TCM and / or TSCM cells such that the engineered immune cells comprise at least about 70% combined TCM and TSCM cells. In some embodiments, engineered immune cells expressing at their cell surface membrane an antigen-specific CAR e enriched in TCM and / or TSCM cells such that the engineered immune cells comprise at least about 75% combined TCM and / or TSCM cells.

[0189] In some embodiments, an engineered immune cell is an inflammatory T-lymphocyte that expresses a CAR. In some embodiments, an engineered immune cell is a cytotoxic T-lymphocyte that expresses a CAR. In some embodiments, an engineered immune cell is a regulatory T-lymphocyte that expresses a CAR. In some embodiments, an engineered immune cell is a helper T-lymphocyte that expresses a CAR. In some embodiments, the immune cell is a memon' T cell that expresses a CAR. In some embodiments, the immune cell is a effector T cell that expresses a CAR. In some embodiments, the immune cell is an effector T cell that expresses a CAR. In some embodiments, the immune cell is an effector memory T cell that expresses a CAR.Genetic modification of CAR T cells

[0190] In some embodiments, an engineered immune cell derived from donor cells having certain gene signatures according to the present disclosure can comprise one or more disrupted or inactivated genes. Manufacture of Engineered Immune Cells (including CAR T cells). In some embodiments, a gene for a target antigen (e g., EGFRvIII, Flt3, WT-1, CD20, CD23, CD30. CD38, CD33, CD133, MHC-WT1, TSPAN10. MHC-PRAME. Livl,ADAMI 0, CHRNA2, LeY, NKGD2D, CS1, CD44v6, ROR1, Claudin-18.2, Mucl7, FAP alpha, Ly6G6D, c6orf23, G6D, MEGT1, NG25, CD19, BCMA, FLT3, CD70, DLL3, or CD34, CD70) can be knocked out to introduce a CAR targeting the same antigen (e.g., a EGFRvIII. Flt3, WT-1, CD20. CD23, CD30, CD38, CD33, CD133, MHC-WT1, TSPAN10, MHC-PRAME, Livl, ADAM10, CHRNA2, LeY, NKGD2D, CSL CD44v6, ROR1, Claudin-18.2, Mucl7, FAP alpha, Ly6G6D, c6orf23, G6D, MEGT1, NG25, CD19, BCMA, FLT3, CD70, DLL3, or CD34, CD70 CAR) to avoid induced CAR activation. As described herein, in some embodiments, an engineered immune cell according to the present disclosure comprises one disrupted or inactivated gene selected from the group consisting of MHC1 (p2M), MHC2 (CIITA), EGFRvIII, Flt3, WT-1, CD20, CD23, CD30, CD38, CD33, CD133, MHC-WT1, TSPAN10, MHC-PRAME, Livl, ADAM10, CHRNA2, LeY, NKGD2D, CS1, CD44v6, ROR1, Claudin-18.2, Mucl7, FAP alpha, Ly6G6D. c6orf23, G6D, MEGT1, NG25. CD19. BCMA, FLT3, CD70, DLL3, or CD34. CD70. TCRa and TCRp and / or expresses a CAR or a multi-chain CAR. In some embodiments, a cell comprises a multichain CAR. In some embodiments, the isolated cell comprises two disrupted or inactivated genes selected from the group consisting of: CD52 and TCRa, CDR52 and TCRP, PD-1 and TCRa. PD-1 and TCRp. MHC-1 and TCRa, MHC-1 and TCRp, MHC2 and TCRa, MHC2 and TCRP and / or expresses a CAR or a multi-chain CAR.

[0191] In some embodiments, an engineered immune cell derived from donor cells having certain gene signatures according to the present disclosure comprises one disrupted or inactivated gene selected from the group consisting of CD52, DLL3, GR, PD-1, CTLA- 4, LAG3, TIM3, BTLA, BY55. TIGIT. B7H5. LAIR1, SIGLEC10, 2B4, HLA. TCRa and TCRP and / or expresses a CAR, a multi-chain CAR and / or a pTa transgene. In some embodiments, an isolated cell comprises polynucleotides encoding polypeptides comprising a multi-chain CAR. In some embodiments, the isolated cell according to the present disclosure comprises two disrupted or inactivated genes selected from the group consisting of: CD52 and GR, CD52 and TCRa, CDR52 and TCRp, DLL3 and CD52, DLL3 and TCRa, DLL3 and TCRp, GR and TCRa, GR and TCRp, TCRa and TCRp, PD-1 and TCRa, PD-1 and TCRP, CTLA-4 and TCRa, CTLA-4 and TCRp, LAG3 and TCRa, LAG3 and TCRp,pTa transgene. In some embodiments the method comprises disrupting or inactivating one or more genes by introducing into the donor cells an endonuclease capable of selectively inactivating a gene by selective DNA cleavage. In some embodiments the endonuclease can be. for example, a zinc finger nuclease (ZFN), megaTAL nuclease, meganuclease, transcription activator-like effector nuclease (TALE-nuclease, or TALEN®), or CRISPR (e.g., Cas9 or Casl2) endonuclease.

[0192] In some embodiments, TCR is rendered not functional in the cells according to the disclosure by disrupting or inactivating TCRa gene and / or TCR gene(s). In some embodiments, a method to obtain modified cells derived from an individual is provided, wherein the cells can proliferate independently of the major histocompatibility complex (MHC) signaling pathway. Modified cells, which can proliferate independently of the MHC signaling pathway, susceptible to be obtained by this method are encompassed in the scope of the present disclosure. Modified cells disclosed herein can be used in for treating patients in need thereof against Host versus Graft (HvG) rejection and Graft versus Host Disease (GvHD); therefore in the scope of the present disclosure is a method of treating patients in need thereof against Host versus Graft (HvG) rejection and Graft versus Host Disease (GvHD) comprising treating said patient by administering to said patient an effective amount of modified cells comprising disrupted or inactivated TCRa and / or TCR[3 genes.

[0193] The present disclosure provides methods of determining the purity of a population of engineered immune cells lacking or having reduced endogenous TCR expression. In some embodiments, the engineered immune cells comprise less than 5.0%, less than 4.0%, less than 3.0%, less than 2.0%. less than 1.0% TCR+ cells, less than 0.9% TCR+ cells, less than 0.8% TCR+ cells, less than 0.7% TCR+ cells, less than 0.6% TCR+ cells, less than 0.5% TCR+ cells, less than 0.4% TCR+ cells, less than 0.3% TCR+ cells, less than 0.2% TCR+ cells, or less than 0.1 % TCR+ cells. Such a population can be a product of the disclosed methods.

[0194] In some embodiments, the immune cells are engineered to be resistant to one or more chemotherapy drugs. The chemotherapy drug can be, for example, a purine nucleotide analogue (PNA), thus making the immune cell suitable for cancer treatment combining adoptive immunotherapy and chemotherapy. Exemplar)’ PNAs include, for example, clofarabine, fludarabine. cyclophosphamide, and cytarabine, alone or in combination. PNAs are metabolized by deoxycytidine kinase (dCK) into mono-, di-, and tri-phosphate PNA. Their tri -phosphate forms compete with ATP for DNA synthesis, act as pro-apoptotic agents,and are potent inhibitors of ribonucleotide reductase (RNR), which is involved in trinucleotide production.

[0195] In some embodiments, isolated cells or cell lines of the disclosure can comprise a pTa or a functional variant thereof. In some embodiments, an isolated cell or cell line can be further genetically modified by disrupting or inactivating the TCRa gene.

[0196] The disclosure also provides engineered immune cells (that are derived from donor cells having a certain gene signature) that comprise any of the CAR polynucleotides described herein. In some embodiments, a CAR can be introduced into an immune cell as a transgene via a plasmid vector. In some embodiments, the plasmid vector can also contain a selection marker which provides for identification and / or selection of cells which received the vector.

[0197] CAR polypeptides can be synthesized in situ in the cell after introduction of polynucleotides encoding the CAR polypeptides into the cell. Alternatively, CAR polypeptides can be produced outside of cells, and then introduced into cells. Methods for introducing a polynucleotide construct into cells are known in the art. In some embodiments, stable transformation methods (e.g., using a lentiviral vector) can be used to integrate the polynucleotide construct into the genome of the cell. In other embodiments, transient transformation methods can be used to transiently express the polynucleotide construct, and the polynucleotide construct not integrated into the genome of the cell. In other embodiments, virus-mediated methods can be used. The polynucleotides can be introduced into a cell by any suitable means such as for example, recombinant viral vectors (e.g., retroviruses, adenoviruses), liposomes, and the like. Transient transformation methods include, for example without limitation, microinjection, electroporation or particle bombardment. Polynucleotides can be included in vectors, such as for example plasmid vectors or viral vectors.

[0198] In some embodiments, isolated nucleic acids are provided comprising a promoter operably linked to a first polynucleotide encoding an antigen binding domain, at least one costimulatory molecule, and an activating domain. In some embodiments, the nucleic acid construct is contained within a viral vector. In some embodiments, the viral vector is selected from the group consisting of retroviral vectors, SFG vectors, adenoviral vectors, lentiviral vectors, adeno-associated virus (AAV) vectors, Herpes virus vectors, and vaccinia virus vectors. In some embodiments, the nucleic acid is contained within a plasmid.

[0199] In some embodiments, the isolated nucleic construct is contained within a viral vector and is introduced into the genome of an engineered immune cell by random integration, e.g., lentiviral- or retroviral-mediated random integration. In some embodiments, the isolated nucleic acid construct is contained in a viral vector or anon-viral vector and is introduced into the genome of an engineered immune cell by sitespecific integration, e.g., adenovirus-mediated site-specific integrationManufacture of Engineered Immune Cells (including CAR T cells)

[0200] Provided herein are methods of analyzing or determining various attributes of donor cells from a donor cell population and / or engineered immune cells from a population of immune cells (including engineered immune cells such as CAR expressing or CAR+ cells). As described herein, engineered immune cells, such as CAR T cells, can be modified to reduce or eliminate expression or activity' of endogenous TCR, and the remaining TCR+ engineered immune cells can be depleted according to the methods described herein, at the end of production. The instant disclosure provides methods of characterizing or analyzing a population of engineered immune cells to characterize the drug product or as part of the manufacturing process. The instant disclosure also provides methods of analyzing or determining other attributes, such as the potency or polyfunctionality of the engineered immune cells to characterize the drug product or as part of the manufacturing process. In some embodiments, the engineered immune cells, such as CAR T cells, are manufactured according to Good Manufacturing Practice (GMP).

[0201] In some embodiments, the disclosed gene signatures and corresponding cellsurface marker combinations are used to detect, quantify, track, enrich, deplete, isolate, and monitor preferentially expanding cells in the source selected from the group consisting of: donor material, in-process manufacturing sample, cell starting material, drug substance and drug product (see FIG. 6C)

[0202] A variety of known techniques can be utilized in making the polynucleotides, polypeptides, vectors, antigen binding domains, immune cells, compositions, and the like according to the disclosure.

[0203] Prior to the in vitro manipulation or genetic modification of the immune cells described herein, the cells can be obtained from a subject. Cells expressing a CAR can be derived from an allogeneic source and can be depleted of endogenous TCR as described herein.a. Source Material

[0204] In some embodiments, the immune cells comprise T cells. T cells can be obtained from a number of sources, including peripheral blood mononuclear cells (PBMCs), bone marrow, lymph nodes tissue, cord blood, thymus tissue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, and tumors. In certain some embodiments, T cells can be obtained from a volume of blood collected from the subject using any number of techniques known to the skilled person, such as FICOLL™ separation.

[0205] Cells can be obtained from the circulating blood of an individual by apheresis. The apheresis product typically contains lymphocytes, including T cells, monocytes, granulocytes, B cells, other nucleated white blood cells, red blood cells, and platelets. In some embodiments, the cells collected by apheresis can be washed to remove the plasma fraction and then placed in an appropriate buffer or media for subsequent processing.

[0206] In certain some embodiments, T cells are isolated from PBMCs by lysing the red blood cells and depleting the monocytes, for example, using centrifugation through a PERCOLL™ gradient. A specific subpopulation of T cells, (e.g., CD28+, CD4+, CD45RA-, and CD45RO+T cells or CD28+, CD4+, CDS+, CD45RA, CD45RO+, and CD62L+ T cells) can be further isolated by positive or negative selection techniques known in the art. For example, enrichment of a T cell population by negative selection can be accomplished with a combination of antibodies directed to surface markers unique to the negatively selected cells. One method for use herein is cell sorting and / or selection via negative magnetic immunoadherence or flow cytometry that uses a cocktail of monoclonal antibodies directed to cell surface markers present on the cells negatively selected. For example, to enrich for CD4+ cells by negative selection, a monoclonal antibody cocktail typically includes antibodies to CD14, CD20, CDllb, CD16, HLA-DR, and CD8. Flow cytometry and cell sorting can also be used to isolate cell populations of interest for use in the present disclosure.

[0207] PBMCs can be used directly for genetic modification with the immune cells (such as CARs or TCRs) using methods as described herein. In certain embodiments, after isolating the PBMCs, T lymphocytes can be further isolated and both cytotoxic and helper T lymphocytes can be sorted into naive, memory, and effector T cell subpopulations either before or after genetic modification and / or expansion. In some embodiments, CD8+ cells are further sorted into naive, stem cell memory, central memory, and effector cells by identify ing cell surface antigens that are associated with each of these types of CD8+ cells. In someembodiments, the expression of phenotypic markers of central memory T cells include CD27, CD45RA, CD45RO, CD62L, CCR7, CD28, CD3, and CD127 and are negative for granzyme B. In some embodiments, stem cell memory T cells are CD45RO-, CD62L+, CD8+ T cells. In some embodiments, central memory T cells are CD45RO+, CD62L+, CD8+ T cells. In some embodiments, effector T cells are negative for CD62L, CCR7, CD28, and CD 127, and positive for granzyme B and perforin. In certain some embodiments, CD4+ T cells are further sorted into subpopulations. For example, CD4+ T helper cells can be sorted into naive, central memory, and effector cells by identifying cell populations that have cell surface antigens.b. Stem cell derived immune cells

[0208] In some embodiments, the immune cells can be derived from embryonic stem (ES) or induced pluripotent stem (iPS) cells. Suitable HSCs, mesenchymal, iPS cells and other types of stem cells can be cultivated immortal cell lines or isolated directly from a patient. Various methods for isolating, developing, and / or cultivating stem cells are known in the art and can be used to practice the present disclosure.

[0209] In some embodiments, the immune cell is an induced pluripotent stem cell (iPSC) derived from a reprogrammed T-cell. In some embodiments, the source material can be an induced pluripotent stem cell (iPSC) derived from a T cell or anon-T cell. The source material can be an embryonic stem cell. The source material can be a B cell, or any other cell from peripheral blood mononuclear cell isolates, hematopoietic progenitor, hematopoietic stem cell, mesenchymal stem cell, adipose stem cell, or any other somatic cell type.c. Genetic Modification of isolated cells

[0210] The donor immune cells, e.g., T cells, of a donor immune cell population can be genetically modified following isolation using known methods, or the donor immune cells can be activated and expanded (or differentiated in the case of progenitors) in vitro prior to being genetically modified. In some embodiments, the isolated donor immune cells are genetically modified to reduce or eliminate expression or activity of endogenous TCRa and / or CD52. In some embodiments, the cells are genetically modified using gene editing technology (e.g., CRISPR / Cas9, CRISPR / Casl2a, a zinc finger nuclease (ZFN), aTALEN, a MegaTAL, a meganuclease) to reduce or eliminate expression or activity of endogenous proteins (e.g., TCRa and / or CD52). In another embodiment, the immune cells, such as T cells, are genetically modified with the chimeric antigen receptors described herein (e.g.,transduced with a viral vector comprising one or more nucleotide sequences encoding a CAR) and then are activated and / or expanded in vitro.

[0211] Following genetic modification to reduce or eliminate expression or activity of an endogenous gene or genes, e.g., endogenous TCRa and / or CD52, to provide engineered immune cells derived from the donor cells, the engineered immune cells may be depleted (according to the methods described herein) of engineered immune cells that do not express one or more of the gene signatures disclosed herein. A depletion step based on gene signature profiling may be performed at any point in the production process.

[0212] Certain methods for making the constructs and engineered immune cells of the disclosure are described in PCT application PCT / US 15 / 14520, the contents of which are hereby incorporated by reference in their entirety.

[0213] It will be appreciated that PBMCs can further include other cytotoxic lymphocytes such as NK cells or NKT cells. An expression vector carrying the coding sequence of a chimeric receptor as disclosed herein can be introduced into a population of human donor T cells, NK cells or NKT cells. Successfully transduced T cells that carry the expression vector can be sorted using flow cytometry to isolate CD3 positive T cells and then further propagated to increase the number of these CAR expressing T cells in addition to cell activation using anti-CD3 antibodies and IL-2 or other methods known in the art as described elsewhere herein. Standard procedures are used for cryopreservation of T cells expressing the CAR for storage and / or preparation for use in a human subject. In one embodiment, the in vitro transduction, culture and / or expansion of T cells are performed in the absence of non-human animal derived products such as fetal calf serum and fetal bovine serum.

[0214] For cloning of polynucleotides, the vector can be introduced into a host cell (an isolated host cell) to allow replication of the vector itself and thereby amplify the copies of the polynucleotide contained therein. The cloning vectors can contain sequence components generally include, without limitation, an origin of replication, promoter sequences, transcription initiation sequences, enhancer sequences, and selectable markers. These elements can be selected as appropriate by a person of ordinary skill in the art. For example, the origin of replication can be selected to promote autonomous replication of the vector in the host cell.

[0215] In certain some embodiments, the present disclosure provides isolated host cells containing the vector provided herein. The host cells containing the vector can be usefulin expression or cloning of the polynucleotide contained in the vector. Suitable host cells can include, without limitation, prokaryotic cells, fungal cells, yeast cells, or higher eukaryotic cells such as mammalian cells, particularly human cells.

[0216] The vector can be introduced to the host cell using any suitable methods known in the art, including DEAE-dextran mediated delivery, calcium phosphate precipitate method, cationic lipids mediated delivery7, liposome mediated transfection, electroporation, microprojectile bombardment, receptor-mediated gene delivery7, delivery7mediated by polylysine, histone, chitosan, and peptides. Standard methods for transfection and transformation of cells for expressron of a vector of interest are well known in the art. In a further embodiment, a mixture of different expression vectors can be used in genetically modifying a donor population of immune effector cells wherein each vector encodes a different CAR. The resulting transduced immune effector cells form a mixed population of engineered cells, with a proportion of the engineered cells expressing more than one different CARs.

[0217] In one embodiment, the disclosure provides a method of storing genetically engineered cells expressing CARs or TCRs. This involves cryopreserving the immune cells such that the cells remain viable upon thawing. A fraction of the immune cells expressing the CARs can be cryopreserved by methods known in the art to provide a permanent source of such cells for the future treatment of patients afflicted with a malignancy. When needed, the cry opreserved transformed immune cells can be thawed, grow n and expanded for more such cells.

[0218] In some embodiments, the cells are formulated by first harvesting them from their culture medium and then washing and concentrating the cells in a medium and container system suitable for administration (a “pharmaceutically acceptable” carrier) in a treatmenteffective amount. Suitable infusion media can be any isotonic medium formulation, normal saline, Normosol™ R (Abbott) or Plasma-Lyte™ A (Baxter), but also 5% dextrose in water or Ringer's lactate can be utilized. The infusion medium can be supplemented with human serum albumin.d. Allogeneic CAR T cells

[0219] The process for manufacturing allogeneic CAR T therapy involves harvesting healthy7, selected, screened and tested donor immune cells, including T cells, from healthy donors. Next, the T cells of the donor immune cells are engineered to express CARs, which recognize certain cell surface proteins that are expressed in hematologic or solid tumors.Allogeneic T cells are gene editing to reduce the risk of graft versus host disease (GvHD) and to prevent allogeneic rejection. A T cell receptor gene (e.g., TCRa, TCR|3) is knocked out to avoid GvHD. The CD52 gene can be knocked out to render the CAR T product resistant to anti-CD52 antibody treatment. Anti-CD52 antibody treatment can therefore be used to suppress the host immune system and allow the CAR T to stay engrafted to achieve full therapeutic impact. The engineered T cells then undergo further processing, which may optionally include a depletion step to remove unwanted T cells that do not express one or more of the gene signatures described herein, as well as a purification step and are ultimately cryopreserved in vials for delivery to patients.Methods of in vitro Sorting

[0220] In some embodiments, provided are methods for in vitro sorting of a population of immune cells, wherein a subset of the population of immune cells comprises engineered immune cells expressing an antigen-specific CARs comprising epitopes specific for monoclonal antibodies (e.g., exemplar}’ mimotope sequences). The method comprises contacting the population of immune cells with a monoclonal antibody specific for the epitopes and selecting the immune cells that bind to the monoclonal antibody to obtain a population of cells enriched in engineered immune cells expressing an antigen-specific CAR.

[0221] In some embodiments, said monoclonal antibody specific for said epitope is optionally conjugated to a fluorophore. In this embodiment, the step of selecting the cells that bind to the monoclonal antibody can be done by Fluorescence Activated Cell Sorting (FACS).

[0222] In some embodiments, said monoclonal antibody specific for said epitope is optionally conjugated to a magnetic particle. In this embodiment, the step of selecting the cells that bind to the monoclonal antibody can be done by Magnetic Activated Cell Sorting (MACS).

[0223] In some embodiments, the mAb used in the method for sorting CAR+ immune cells is chosen from alemtuzumab, ibritumomab tiuxetan, muromonab-CD3, tositumomab, abciximab, basiliximab, brentuximab vedotin, cetuximab, infliximab, rituximab, bevacizumab, certolizumab pegol, daclizumab, eculizumab, efalizumab, gemtuzumab, natalizumab. omalizumab, palivizumab, ranibizumab, tocilizumab, trastuzumab, vedolizumab, adalimumab, belimumab, canakinumab, denosumab, golimumab, ipilimumab, ofatumumab, panitumumab, QBEND-10 and ustekinumab. In other embodiments the mAb binds to TCRa or TCRb.

[0224] In some embodiments, the population C AR-expressing immune cells obtained when using the method for in vitro sorting CAR-expressing immune cells described above, comprises at least 70%, 75%, 80%, 85%, 90%, 95% of CAR-expressing immune cells. In some embodiments, the population of CAR-expressing immune cells obtained when using the method for in vitro sorting CAR-expressing immune cells, comprises at least 85% CAR-expressing immune cells.

[0225] In some embodiments, the population of CAR-expressing immune cells obtained when using the method for in vitro sorting CAR-expressing immune cells described above shows increased cytotoxic activity in vitro compared with the initial (non-sorted) cell population. In some embodiments, said cytotoxic activity in vitro is increased by 10%, 20%, 30%, 40% or 50%. In some embodiments, the immune cells are T-cells.

[0226] In some embodiments, the mAbs are previously bound onto a support or surface. Non-limiting examples of solid support can include a bead, agarose bead, a magnetic bead, a plastic welled plate, a glass welled plate, a ceramic welled plate, a column, or a cell culture bag.

[0227] The CAR-expressing immune cells to be administered to the recipient can be enriched in vitro from the source population. Methods of expanding source populations can include selecting cells that express an antigen such as CD34 antigen, using combinations of density centrifugation, immuno-magnetic bead purification, affinity chromatography, and fluorescent activated cell sorting.

[0228] Flow cytometry can be used to quantify specific cell types within a population of cells. In general, flow cytometry is a method for quantifying components or structural features of cells primarily by optical means. Since different cell types can be distinguished by quantifying structural features, flow cytometry and cell sorting can be used to count and sort cells of different phenotypes in a mixture.

[0229] In some embodiments, the method used for sorting T cells expressing CAR is the Magnetic- Activated Cell Sorting (MACS). Magnetic-activated cell sorting (MACS) is a method for separation of various cell populations depending on their surface antigens (e.g., CD molecules) by using superparamagnetic nanoparticles and columns. MACS can be used to obtain a pure cell population. Cells in a single-cell suspension can be magnetically labeled with microbeads. The sample is applied to a column composed of ferromagnetic spheres, which are covered with a cell-friendly coating allowing fast and gentle separation of cells. The unlabeled cells pass through while the magnetically labeled cells are retained within thecolumn. The flow-through can be collected as the unlabeled cell fraction. After a washing step, the column is removed from the separator, and the magnetically labeled cells are eluted from the column.

[0230] Detailed protocol for the purification of specific cell population such as T-cell can be found in Basu S et al. (2010). (Basu S, Campbell HM, Dittel BN, Ray A. Purification of specific cell population by fluorescence activated cell sorting (FACS). J Vis Exp. (41): 1546).Pharmaceutical Compositions and Therapy

[0231] In some embodiments, the engineered immune cells described herein are formulated by first harvesting them from their culture medium and then washing and concentrating the cells in a medium and container system suitable for administration (a “pharmaceutically acceptable7’ carrier) in a treatment-effective amount. Suitable infusion media can be any isotonic medium formulation, typically normal saline, Normosol™ R (Abbott) or Plasma-Lyte™ A (Baxter), but also 5% dextrose in water or Ringer's lactate can be utilized. The infusion medium can be supplemented with human serum albumin.

[0232] The CAR expressing cell populations of the present disclosure can be administered either alone, or as a pharmaceutical composition in combination with diluents and / or with other components such as IL-2 or other cytokines or cell populations. Pharmaceutical compositions of the present disclosure can comprise a CAR or TCR expressing cell population, such as T cells, as described herein, in combination with one or more pharmaceutically or physiologically acceptable carriers, diluents or excipients. Such compositions can comprise buffers such as neutral buffered saline, phosphate buffered saline and the like; carbohydrates such as glucose, mannose, sucrose or dextrans, mannitol; proteins; polypeptides or amino acids such as glycine; antioxidants; chelating agents such as EDTA or glutathione; adjuvants (e.g., aluminum hydroxide); and preservatives. Compositions of the present disclosure are preferably formulated for intravenous administration.

[0233] The pharmaceutical compositions (solutions, suspensions or the like), can include one or more of the following: sterile diluents such as water for injection, saline solution, preferably physiological saline, Ringer's solution, isotonic sodium chloride, fixed oils such as synthetic mono- or diglycerides which can serve as the solvent or suspending medium, polyethylene glycols, glycerin, propylene glycol or other solvents; antibacterial agents such as benzyl alcohol or methyl paraben; antioxidants such as ascorbic acid orsodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. The parenteral preparation can be enclosed in ampules, disposable syringes or multiple dose vials made of glass or plastic. An injectable pharmaceutical composition is preferably sterile.

[0234] In some embodiments, the pharmaceutical composition described herein is for use as a medicament in the treatment of a cancer. In some embodiments the pharmaceutical composition described herein is for use as a medicament in treating a cancer selected from the following group consisting of: leukemia, lymphoma, multiple myeloma, melanoma, breast cancer, lung cancer, colorectal cancer, pancreatic cancer, ovarian cancer, prostate cancer, and glioblastoma.Methods of Treatment

[0235] The disclosure comprises methods for treating or preventing a disease (e.g., cancer) in a patient, comprising administering to a patient in need thereof an effective amount of engineered immune cells (e.g.. CAR T cells, or engineered immune cells comprising a CAR disclosed herein) that have been derived from donor cells having a gene signature as described herein. In some embodiments, the effective amount of CAR T cells or engineered immune cells have been analyzed for various attributes according to the methods described in the instant disclosure. In some embodiments, the CAR T cell drug product for therapeutic use has been analyzed for various attributes, such as a gene signature, potency or polyfunctionality according to the methods described in the instant disclosure. In some embodiments, the CAR T cells are TCR- CAR T cells, and the CAR T drug product for therapeutic use has been analyzed for various attributes, such as the amount or percentage of remaining TCR+ CAR T cells and / or potency or polyfunctionality according to the methods described in the instant disclosure.

[0236] Methods are provided for treating diseases or disorders, including cancer. In some embodiments, the disclosure relates to creating a T cell-mediated immune response in a subject, comprising administering an effective amount of the engineered immune cells of the present application to the subject. In some embodiments, the T cell-mediated immune response is directed against a target cell or cells. In some embodiments, the engineered immune cell comprises a chimeric antigen receptor (CAR). In some embodiments, the target cell is a tumor cell. In some aspects, the disclosure comprises a method for treating or preventing a malignancy, said method comprising administering to a subject in need thereofan effective amount of at least one isolated antigen binding domain described herein. In some aspects, the disclosure comprises a method for treating or preventing a malignancy, said method comprising administering to a subject in need thereof an effective amount of at least one immune cell, wherein the immune cell comprises at least one chimeric antigen receptor, T cell receptor, and / or isolated antigen binding domain as described herein. In some embodiments, CAR containing immune cells of the disclosure can be used to treat small cell lung cancer, melanoma, low grade gliomas, glioblastoma, medullary7thyroid cancer, carcinoids, dispersed neuroendocrine tumors in the pancreas, bladder and prostate, testicular cancer, and lung adenocarcinomas with neuroendocrine features. In exemplary embodiments, the CAR containing immune cells, e.g., CAR T cells of the disclosure are used to treat small cell lung cancer.

[0237] Also provided are methods for reducing the size of a tumor in a subject, comprising administering to the subject an engineered cell of the present disclosure to the subject, wherein the cell comprises a chimeric antigen receptor comprising an antigen binding domain and binds to an antigen on the tumor.

[0238] In some embodiments, the subject has a solid tumor, or a blood malignancy such as lymphoma or leukemia. In some embodiments, the engineered cell is delivered to a tumor bed. In some embodiments, the cancer is present in the bone marrow of the subject. In some embodiments, the engineered cells are autologous immune cells, e.g., autologous T cells. In some embodiments, the engineered cells are allogeneic immune cells, e.g., allogeneic T cells. In some embodiments, the engineered cells are heterologous immune cells, e.g., heterologous T cells. In some embodiments, the engineered cells of the present application are transfected or transduced in vivo. In other embodiments, the engineered cells are transfected or transduced ex vivo. As used herein, the term "in vitro cell” refers to any cell which is cultured ex vivo.

[0239] In some embodiments, the subject has or suspected of having a cancer. In some embodiments, the cancer is selected from the group consisting of leukemia, lymphoma, multiple myeloma, melanoma, breast cancer, lung cancer, colorectal cancer, pancreatic cancers, ovarian cancer, prostate cancer or glioblastoma.

[0240] A “therapeutically effective amount," “effective dose," “effective amount,” or “therapeutically effective dosage” of a therapeutic agent, e.g., engineered CART cells, is any amount that, when used alone or in combination with another therapeutic agent, protects a subject against the onset of a disease or promotes disease regression evidenced by a decreasein severity of disease symptoms, an increase in frequency and duration of disease symptom-free periods, or a prevention of impairment or disability' due to the disease affliction. The ability of a therapeutic agent to promote disease regression can be evaluated using a variety of methods known to the skilled practitioner, such as in human subjects during clinical trials, in animal model systems predictive of efficacy in humans, or by assaying in in vitro assays.

[0241] The terms “patient” and “subj ecf ’ are used interchangeably and include human and non-human animal subjects as well as those with formally diagnosed disorders, those without formally recognized disorders, those receiving medical attention, those at risk of developing the disorders, etc.

[0242] The term “treat” and “treatment” includes therapeutic treatments, prophylactic treatments, and applications in which one reduces the risk that a subject will develop a disorder or other risk factor. Treatment does not require the complete curing of a disorder and encompasses embodiments in which one reduces symptoms or underlying risk factors. The term “prevent” does not require the 100% elimination of the possibility of an event. Rather, it denotes that the likelihood of the occurrence of the event has been reduced in the presence of the compound or method.

[0243] The number of cells will depend upon the desired use for which the composition is intended, and the type of cells included therein. The density of the desired cells is typically greater than 106cells / ml and generally is greater than 107cells / ml, generally 108cells / ml or greater. The clinically relevant number of immune cells can be apportioned into multiple infusions that cumulatively equal or exceed 105, 106, 107, 108, 109, 1010, 1011, or 1012cells. In some aspects of the present disclosure, particularly since all the infused cells will be redirected to a particular target antigen, lower numbers of cells, in the range of 106 / kilogram (ICri-lO11per patient) can be administered. CAR treatments can be administered multiple times at dosages within these ranges.

[0244] In some embodiments, the therapeutically effective amount of the CAR T cells is about 1 X 103cells / kg, about 2 X 105cells / kg, about 3 X 105cells / kg, about 4 X 105cells / kg, about 5 X 103cells / kg, about 6 X 105cells / kg, about 7 X 10scells / kg, about 8 X 105cells / kg, about 9 X 103cells / kg, 2 X 106cells / kg, about 3 X 106cells / kg, about 4 X 106cells / kg, about 5 X 106cells / kg, about 6 X 106cells / kg, about 7 X 106cells / kg, about 8 X 106cells / kg, about 9 X 106cells / kg. about 1 X 107cells / kg, about 2 X 107cells / kg, about 3 X 107cells / kg, about 4 X 107cells / kg, about 5 X 107cells / kg, about 6 X 107cells / kg, about 7 X 107cells / kg, about 8 X 107cells / kg, or about 9 X 107cells / kg.

[0245] In some embodiments, target doses for CAR+ / CAR T+ / TCR+ cells range from 1X106-2X108cells / kg, for example 2xl06cells / kg. It will be appreciated that doses above and below this range can be appropriate for certain subjects, and appropriate dose levels can be determined by the healthcare provider as needed. Additionally, multiple doses of cells can be provided in accordance with the disclosure.

[0246] Engineered immune cells expressing one or more of the gene signatures disclosed herein, or any combination thereof, preferentially expand in vivo following administration. This selective expansion may enhance the persistence and functionality of the administered cell population, thereby contributing to improved therapeutic efficacy. In certain embodiments, the in vivo expansion of cells characterized by the disclosed gene signature correlates with, or results in, clinically meaningful outcomes, including but not limited to tumor regression, disease stabilization, or other indicators of therapeutic benefit.

[0247] In some embodiments, the preferential expansion of engineered immune cells expressing one or more of the disclosed gene signatures promotes anti-tumor immune responses in subjects with cancer, including hematologic malignancies and solid tumors.

[0248] In some aspects, the disclosure comprises a pharmaceutical composition comprising at least one antigen binding domain as described herein and a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical composition further comprises an additional active agent.

[0249] The CAR expressing cell populations of the present disclosure can be administered either alone, or as a pharmaceutical composition in combination with diluents and / or with other components such as IL-2 or other cytokines or cell populations. Pharmaceutical compositions of the present disclosure can comprise a CAR or TCR expressing cell population, such as T cells, as described herein, in combination with one or more pharmaceutically or physiologically acceptable carriers, diluents or excipients. Such compositions can comprise buffers such as neutral buffered saline, phosphate buffered saline and the like; carbohydrates such as glucose, mannose, sucrose or dextrans, mannitol; proteins; polypeptides or amino acids such as glycine; antioxidants; chelating agents such as EDTA or glutathione; adjuvants (e.g., aluminum hydroxide); and preservatives. Compositions of the present disclosure are preferably formulated for intravenous administration.

[0250] The pharmaceutical compositions (solutions, suspensions or the like), can include one or more of the following: sterile diluents such as water for injection, salinesolution, preferably physiological saline, Ringer's solution, isotonic sodium chloride, fixed oils such as synthetic mono- or diglycerides which can serve as the solvent or suspending medium, polyethylene glycols, glycerin, propylene glycol or other solvents; antibacterial agents such as benzyl alcohol or methyl paraben; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. The parenteral preparation can be enclosed in ampules, disposable syringes or multiple dose vials made of glass or plastic. An injectable pharmaceutical composition is preferably sterile.

[0251] In some embodiments, upon administration to a patient, engineered immune cells expressing at their cell surface any one of the antigen-specific CARs described herein can reduce, kill or lyse endogenous antigen-expressing cells of the patient. In one embodiment, a percentage reduction or lysis of antigen-expressing endogenous cells or cells of a cell line expressing an antigen by engineered immune cells expressing any one of an antigen-specific CARs described herein is at least about or greater than 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%. In one embodiment, a percentage reduction or lysis of antigen-expressing endogenous cells or cells of a cell line expressing an antigen by engineered immune cells expressing antigenspecific CARs is about 5% to about 95%, about 10% to about 95%, about 10% to about 90%, about 10% to about 80%, about 10% to about 70%, about 10% to about 60%, about 10% to about 50%, about 10% to about 40%, about 20% to about 90%, about 20% to about 80%, about 20% to about 70%, about 20% to about 60%. about 20% to about 50%, about 25% to about 75%, or about 25% to about 60%. In one embodiment, the endogenous antigenexpressing cells are endogenous antigen-expressing bone marrow cells.

[0252] In one embodiment, the percent reduction or lysis of target cells, e.g., a cell line expressing an antigen, by engineered immune cells expressing at their cell surface membrane an antigen-specific CAR of the disclosure can be measured using the assay disclosed herein.

[0253] The methods can further comprise administering one or more chemotherapeutic agent. In certain some embodiments, the chemotherapeutic agent is a lymphodepleting (preconditioning) chemotherapeutic. For example, methods of conditioning a patient in need of a T cell therapy comprising administering to the patient specified beneficial doses of cyclophosphamide (between 200 mg / m2 / day and 2000mg / m2 / day, about 100 mg / m2 / day and about 2000 mg / m2 / day; e.g, about 100 mg / m2 / day, about 200 mg / m2 / day, about 300 mg / m2 / day, about 400 mg / m2 / day, about 500 mg / m2 / day, about 600 mg / m2 / day, about 700 mg / m2 / day, about 800 mg / m2 / day, about 900 mg / m2 / day, about 1000 mg / m2 / day. about 1500 mg / m2 / day or about 2000 mg / m2 / day) and specified doses of fludarabine (between 20 mg / m2 / day and 900 mg / m2 / day, between about 10 mg / m2 / day and about 900 mg / m2 / day; e.g., about 10 mg / m2 / day, about 20 mg / m2 / day, about 30 mg / m2 / day, about 40 mg / m2 / day, about 40 mg / m2 / day, about 50 mg / m2 / day, about 60 mg / m2 / day, about 70 mg / m2 / day, about 80 mg / m2 / day. about 90 mg / m2 / day, about 100 mg / m2 / day, about 500 mg / m2 / day or about 900 mg / m2 / day). A preferred dose regimen involves treating a patient comprising administering daily to the patient of about 300 mg / m2 / day of cyclophosphamide and about 30 mg / m2 / day of fludarabine for three days prior to administration of a therapeutically effective amount of engineered T cells to the patient.

[0254] In some embodiments, lymphodepletion further comprises administration of a CD52 antibody. In some embodiments, the CD52 antibody is alemtuzumab. In some embodiments, the CD52 antibody is administered at a dose of about 13 mg / day IV.

[0255] In other embodiments, the antigen binding domain, transduced (or otherw ise engineered) cells and the chemotherapeutic agent are administered each in an amount effective to treat the disease or condition in the subject.

[0256] In certain some embodiments, compositions comprising CAR-expressing immune effector cells disclosed herein can be administered in conjunction with any number of chemotherapeutic agents, which can be administered in any order. Examples of chemotherapeutic agents include alkylating agents such as thiotepa and cyclophosphamide (CYTOXAN™); alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, trietylenephosphoramide. triethylenethiophosphaoramide and trimethylolomelamine resume; nitrogen mustards such as chlorambucil, chlomaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, ranimustine; antibiotics such as aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, calicheamicin, carabicin, carminomycin, carzinophilin, chromomycins, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin, epirubicin, esorubicin,idarubicin, marcellomycin, mitomycins, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; anti-metabolites such as methotrexate and 5-fluorouracil (5-FU): folic acid analogues such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, 5-FU; androgens such as calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone; antiadrenals such as aminoglutethimide, mitotane, trilostane; folic acid replenisher such as frolinic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elformithine; elliptinium acetate; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidamine; mitoguazone; mitoxantrone; mopidamol; nitracrine; pentostatin; phenamet; pirarubicin; podophyllinic acid: 2-ethylhydrazide; procarbazine; PSK®; razoxane; sizofiran; spirogermanium; tenuazonic acid; triaziquone; 2, 2', 2"-trichlorotriethylamine; urethan; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside (“Ara-C”); cyclophosphamide: thiotepa: taxoids, e.g., paclitaxel (TAXOL™, Bristol-Myers Squibb) and doxetaxel (TAXOTERE®, Rhone-Poulenc Rorer); chlorambucil; gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum analogs such as cisplatin and carboplatin; vinblastine; platinum; etoposide (VP- 16); ifosfamide; mitomycin C; mitoxantrone; vincristine; vinorelbine; navelbine; novantrone; teniposide; daunomycin; aminopterin; xeloda; ibandronate; CPT-11; topoisomerase inhibitor RF S2000; difluoromethylomithine (DMFO); retinoic acid derivatives such as Targretin™ (bexarotene), Panretin™, (alitretinoin); ONTAK™ (denileukin diftitox); esperamicins; capecitabine; and pharmaceutically acceptable salts, acids or derivatives of any of the above. Also included in this definition are anti-hormonal agents that act to regulate or inhibit hormone action on tumors such as anti -estrogens including for example tamoxifen, raloxifene, aromatase inhibiting 4(5)-imidazoles, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone, and toremifene (Fareston); and anti-androgens such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin; and pharmaceutically acceptable salts, acids or derivatives of any of the above. Combinations of chemotherapeutic agents are also administered where appropriate, including, but not limited to CHOP, i.e.,Cyclophosphamide (Cytoxan®), Doxorubicin (hydroxydoxorubicin). Vincristine (Oncovin®), and Prednisone.

[0257] In some embodiments, the chemotherapeutic agent is administered at the same time or within one week after the administration of the engineered cell, polypeptide, or nucleic acid. In other embodiments, the chemotherapeutic agent is administered from 1 to 4 weeks or from 1 week to 1 month, 1 week to 2 months, 1 week to 3 months, 1 week to 6 months, 1 week to 9 months, or 1 week to 12 months after the administration of the engineered cell, polypeptide, or nucleic acid. In other embodiments, the chemotherapeutic agent is administered at least 1 month before administering the cell, polypeptide, or nucleic acid. In some embodiments, the methods further comprise administering two or more chemotherapeutic agents.

[0258] A variety' of additional therapeutic agents can be used in conjunction with the compositions described herein. For example, potentially useful additional therapeutic agents include PD-1 inhibitors such as nivolumab (Opdivo®), pembrolizumab (Keytruda®), pembrolizumab, pidilizumab, and atezolizumab (Tcentriq®).

[0259] Additional therapeutic agents suitable for use in combination with the disclosure include, but are not limited to, ibrutinib (Imbruvica®), ofatumumab(Arzerra®, rituximab (Rituxan®), bevacizumab (Avastin®), trastuzumab (Herceptin®), trastuzumab emtansine (KADCYLA®, imatinib (Gleevec®), cetuximab (Erbitux®, panitumumab) (Vectibix®), catumaxomab, ibritumomab, ofatumumab, tositumomab, brentuximab, alemtuzumab, gemtuzumab, erlotinib, gefitinib, vandetanib. afatinib, lapatinib, neratinib, axitinib, masitinib, pazopanib, sunitinib, sorafenib, toceranib, lestaurtinib, axitinib, cediranib, lenvatinib, nintedanib, pazopanib, regorafenib, semaxanib, sorafenib, sunitinib, tivozanib, toceranib, vandetanib, entrectinib, cabozantinib, imatinib, dasatinib, nilotinib, ponatinib, radotinib, bosutinib. lestaurtinib, ruxolitinib, pacritinib, cobimetinib, selumetinib, trametinib, binimetinib, alectinib, ceritinib, crizotinib. aflibercept, adipotide, denileukin diftitox, mTOR inhibitors such as Everolimus and Temsirolimus, hedgehog inhibitors such as sonidegib and vismodegib, CDK inhibitors such as CDK inhibitor (palbociclib).

[0260] In some embodiments, the composition comprising CAR-containing immune cells can be administered with a therapeutic regimen to prevent cytokine release syndrome (CRS) or neurotoxicity. The therapeutic regimen to prevent cytokine release syndrome (CRS) or neurotoxicity can include lenzilumab, tocilizumab, atrial natriuretic peptide (ANP), anakinra, iNOS inhibitors (e.g., L-NIL or 1400W). In additional embodiments, the compositioncomprising CAR-containing immune cells can be administered with an anti-inflammatory agent. Anti-inflammatory agents or drugs include, but are not limited to, steroids and glucocorticoids (including betamethasone, budesonide, dexamethasone, hydrocortisone acetate, hydrocortisone, hydrocortisone, methylprednisolone, prednisolone, prednisone, triamcinolone), nonsteroidal anti-inflammatory drugs (NSAIDS) including aspirin, ibuprofen, naproxen, methotrexate, sulfasalazine, leflunomide, anti-TNF medications, cyclophosphamide and mycophenolate. Exemplary' NSAIDs include ibuprofen, naproxen, naproxen sodium, Cox-2 inhibitors, and sialylates. Exemplary analgesics include acetaminophen, oxycodone, tramadol of proporxyphene hydrochloride. Exemplary glucocorticoids include cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, or prednisone. Exemplary' biological response modifiers include molecules directed against cell surface markers (e.g., CD4, CD5, etc.), cytokine inhibitors, such as the TNF antagonists, (e.g.. etanercept (ENBREL®), adalimumab (HUMIRA®) and infliximab (REMICADE®), chemokine inhibitors and adhesion molecule inhibitors. The biological response modifiers include monoclonal antibodies as well as recombinant forms of molecules. Exemplary DMARDs include azathioprine, cyclophosphamide, cyclosporine, methotrexate, penicillamine, leflunomide, sulfasalazine, hydroxychloroquine, Gold (oral (auranofin) and intramuscular) and minocycline.

[0261] In certain embodiments, the compositions described herein are administered in conjunction with a cytokine. Examples of cytokines are lymphokines, monokines, and traditional polypeptide hormones. Included among the cytokines are growth hormones such as human growth hormone, N-methionyl human growth hormone, and bovine growth hormone; parathyroid hormone; thyroxine; insulin; proinsulin; relaxin; prorelaxin; glycoprotein hormones such as follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), and luteinizing hormone (LH); hepatic growth factor (HGF); fibroblast growth factor (FGF); prolactin; placental lactogen; mullerian-inhibiting substance; mouse gonadotropin-associated peptide; inhibin; activin; vascular endothelial growth factor; integrin; thrombopoietin (TPO); nerve growth factors (NGFs) such as NGF-beta; plateletgrowth factor; transforming growth factors (TGFs) such as TGF -alpha and TGF-beta; insulinlike growth factor-I and -II; erythropoietin (EPO); osteoinductive factors; interferons such as interferon-alpha, beta, and -gamma; colony stimulating factors (CSFs) such as macrophage-CSF (M-CSF); granulocyte-macrophage-CSF (GM-CSF); and granulocyte-CSF (G-CSF); interleukins such as IL-1, IL- 1 alpha, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL- 10, IL-11, IL-12; IL-15, IL-21 a tumor necrosis factor such as TNF-alpha or TNF-beta; and other polypeptide factors including LIF and kit ligand (KL). As used herein, the term cytokine includes proteins from natural sources or from recombinant cell culture, and biologically active equivalents of the native sequence cytokines.Kits and Articles of Manufacture

[0262] The present disclosure provides kits comprising reagents for analyzing cell populations described herein, including donor cell populations and engineered cell populations, including CAR T drug products. In some embodiments, the kit comprises one or more reagents for the detection of one or more gene signatures described herein. The reagents may be antigen binding molecules having specificity, such as an antibody as described herein, to the one or more cell surface proteins associated with one of the gene signatures described herein. In some embodiments, the kit further comprises one or more reagents for the detection of the CAR. In some embodiments, the kit further comprises one or more reagents for the detection of TCRab. In some embodiments, the kit comprises one or more reagent for analyzing the cell populations described herein according to the methods described herein, wherein the one or more reagent is conjugated with a detection label. The kit may also comprise instructions on the use of the reagents to detect levels of the one or more gene signatures, wherein the detected level indicates a percentage of expression for one or more gene signatures described herein. In another embodiment, the kit may further comprise reagents for measuring the in vitro functionality of an engineered immune cell, e.g., a CAR T cell. The measured in vitro functionality may comprise in vitro cytotoxicity, mitochondrial fitness, and / or cytokine secretion profiling.

[0263] The present disclosure also provides kits comprising any of the cultured immune cells or engineered immune cells described herein, and pharmaceutical compositions of the same. In some exemplary embodiments, a kit of the disclosure comprises allogeneic CAR T cells for administering to a subject.

[0264] The present disclosure also provides kits comprising any of the cultured immune cells or engineered immune cells described herein, and pharmaceutical compositions of the same. In some exemplary’ embodiments, a kit of the disclosure comprises allogeneic CAR T cells for administering to a subject.

[0265] The present application further provides articles of manufacture comprising any one of the therapeutic compositions or kits described herein. Examples of an article of manufacture include vials (e.g. sealed vials).The following examples are offered for illustrative purposes only. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description.Definitions

[0266] As used herein, the terms “a” and “an” are used to mean one or more. For example, a reference to “a cell” or “an antibody” means “one or more cells” or “one or more antibodies.”

[0267] As used herein, the term “labeling agent” generally refers to an agent capable of interacting with a component of a cell including, without limitation, the cell membrane, a molecule on and / or within the cell, an intracellular molecule of the cell, etc. The interaction between the agent and the cell component may be a covalent interaction or a non-covalent interaction, a reversible interaction, or an irreversible interaction. The labeling agent may be specific to the cell component including, without limitation, a biological molecule of the cell (e.g., a polypeptide, a nucleic acid, a lipid, etc.). In some embodiments, the labeling agent may be an agent having specificity to a biological target, such as an antibody or an antibody fragment. In one embodiment, the labeling agent is an agent having specificity to a cell surface molecule, e.g., a cell surface or cell membrane protein. In some cases, the labelling agent can include one or more detectable labels. In some embodiments, the labeling agent comprises an antibody, optionally conjugated with a detectable label.

[0268] In some embodiments, the detectable label is selected from the group consisting of a fluorescent label, a photochromic compound, a proteinaceous fluorescent label, a molecule capable of a colorimetric reaction, a magnetic label, a radiolabel, an oligonucleotide label, and a hapten. In some embodiments, the fluorescent label is selected from the group consisting of an Atto dye. an Alexafluor dye, quantum dots, Hydroxycoumarin, Aminocouramin, Methoxy courmarin, Cascade Blue, Pacific Blue, Pacific Orange, Lucifer Yellow, NBD, R-Phycoerythrin (PE), PE-Cy5 conjugates, PE-Cy7 conjugates. Red 613, PerCP, TruRed, FluorX, Fluorescein, BODIPY-FL, Cy2, Cy3, Cy3B, Cy3.5, Cy5, Cy5.5, Cy7, TRITC, X-Rhodamine, Lissamine Rhocamine B, Texas Red, Allophycocyanin (APC), APC-Cy7 conjugates, Indo-1, Fluo-3, Fluo-4, DCFH, DHR, SNARF, GFP (Y66H mutation),Green, ZsGreenl, TagYFP, EYFP, Topaz, Venus, mCitrine, YPet, TurboYFP, ZsYellowl, Kusabira Orange, mOrange, Allophycocyanin (APC), mKO, TurboRFP, tdTomato, TagRFP, DsRed monomer, DsRed2 (“RFP”), mStrawberry, TurboFP602, AsRed2, mRFPl, J-Red, R-phycoerythrin (RPE), B-phycoeryhring (BPE), mCherry, HcRedl, Katusha, P3, Peridinin Chlorophyll (PerCP), mKate (TagFP635), TurboFP635, mPlum, and mRaspberry. In some embodiments, the one or more labeling agents are used for flow cytometry. The one or more labels may be directly or indirectly coupled to or conjugated to labelling agents. For an indirect format, the one or more labels may be coupled to or conjugated to a molecule that can bind to the labeling agent. For example, the label may be conjugated to an oligonucleotide sequence that is complementary to another oligonucleotide sequence from an oligonucleotide conjugated to the labeling agent (e.g., an antibody conjugated to an oligonucleotide). Labels may also be used with the methods and compositions of the present disclosure in the context of binding agents, such as secreted molecule binding agents, e.g.. secreted cytokine binding agents.EXAMPLESExample 1: Identifying gene signature of preferentially expanding CAR T cells MethodsPatient samples

[0269] Samples for this work were derived from 44 patients across three different trials -ALPHA2 (NCT04416984), UNIVERSAL (NCT04093596) and TRAVERSE (NCT04696731). ALPHA2 is a Phase 1 / 2 study evaluating anti-CD19 allogeneic CAR T cells in patients with relapsed / refractory large B-cell lymphoma. UNIVERSAL is a Phase 1 study evaluating anti-BCMA allogeneic CAR T cells in patients with relapsed / refractory multiple myeloma. TRAVERSE is a Phase 1 study evaluating anti-CD70 allogeneic CAR T cells in patients with advanced or metastatic clear cell renal cell carcinoma. Analysis in this work included patients dosed with three CAR T infusion product (IP) lots of the anti-CD19 allogeneic CAR T cells (Lots 1-3), two IP lots of the anti-BCMA allogeneic CAR T cells (Lots 1-2) and two IP lots of the anti-CD70 allogeneic CAR T cells (Lots 1-2).T cell receptor sequencing and identification of preferentially expanding clones

[0270] Sequencing of complementarity determining region 3 (CDR3) of the T cell Receptor (3 chain (TCR ) in genomic DNA extracted from whole blood samples, formalin-fixed paraffin embedded (FFPE) tumor biopsy samples or CAR T infusion products (IPs) was performed by Adaptive Biotechnologies (Seattle, Wash.) using the ImmunoSEQ platform. For each patient, baseline and post CAR T infusion samples were sent for T cell receptor sequencing (TCRseq). Clones were identified and compared across samples using the CDR3amino acid sequence. For each IP lot, preferentially expanding clones were identified using the following two criteria:(a) an increase in frequency of the clone at either Day 7 or Day 14 post-infusion, relative to its frequency in the IP (Fisher's test, p<0.05). and(b) the clone being identified as an expanding clone in at least 3* or more patients given the same IP (*2 or more if only 3 patients were available for analysis).For tumor samples, only biopsies in the range of Days 7-10 post-infusion were available for TCRseq and thus identification of preferentially expanding clones was based on a single timepoint in each patient. At the IP lot level, it was required that a clone was identified as expanding in at least two or more patients’ tumor samples to be called preferentially expanding.Single cell TCR and CITE-seq characterization and analysis of Infusion Product lots

[0271] CAR T products were thawed and washed in X-vivo media (Lonza, Cat#04-380Q). Cells were resuspended in cell staining buffer (BioLegend, Cat#420201) and stained with TotalSeq-C antibody cocktail (BioLegend, custom order -204 antibodies) following the manufacture’s protocol. 20,000 cells were targeted for each sample. Single cell antibody derived tags (ADTs), V(D)J, and gene expression libraries were prepared with Chromium Next GEM Single Cell 5’ HT Reagent v2 kits (lOx Genomics) following the manufacturer's User Guide. Library samples were sequenced on NextSeq2000 (Illumina). The data were processed using Cellranger multi pipeline and aligned with a custom GRCh38 human genome reference containing the anti-CD19, anti-BCMA and anti-CD19 CAR constructs. The custom GRCh38 human genome reference containing the anti-CD19, anti-BCMA and anti-CD19 CAR constructs was generated by manually adding the CAR constructs to the genome. The single cell data was then aligned the custom genome. Processing, filtering, clustering and annotation of the multimodal data were performed in R using Seurat (v5.0.1). Preferentially expanding clones identified from patients using TCRseq for each IP lot were mapped to the corresponding single cell TCR data for the IP using the CDR3 amino acid sequences. Enrichment of preferentially expanding clones at the cluster level was assessed using a Fisher’s test and expanding clone clusters were identified for each IP lot. FIGs. 1A-1E show TCRseq identified expanding clones in multiple patients across five different IP lots and two different CAR Ts. When the expanding TCR clonotypes were mapped to the infusion product (IP) single cell clusters, they were contained within certain clusters of cells annotated as CD8 T cells. Dimensionality reduction and visualization algorithm Uniform ManifoldApproximation and Projection (UMAP) was used to visualize the IP single cell data and highlight clusters enriched with expanding clones. Differential expression analyses were performed to compare expanding clone clusters to the ones that did not expand. Heatmaps were used to visualize and qualitatively assess consistency of phenotypic signatures across lots.

[0272] To identify a consistent signature of expanding clones across different IP lots, a robust, multi-step machine learning based approach was utilized using CatBoost algorithm. Specifically, four out of the seven IP lots were used to train a signature, and the remaining three IP lots were used for testing the performance of the signature. For training, a roundrobin leave-one-out (LOO) approach was undertaken where three out of the four lots were used for training and recursive feature elimination (RFE), and the fourth lot was used for testing. This resulted in four rounds of LOO RFE and four signatures. A consensus gene signature was identified as an intersection of the four signatures. This consensus signature was then tested in the remaining three IP lots visually (AddModuleScore_UCell from UCell R package) and quantitatively (Precision, Recall and PR AUC using CatBoost). Based on visual inspection, genes (TRDV2 and TRGV9) were manually added for better discrimination from Gamma-delta T cells. For testing and evaluating the signatures, TCRseq-based expanding clone clusters were used as ground truth. Additional analysis of the resulting consensus signature was performed in the four training lots and one test lot (to incorporate products for all three targets) using RFE to determine the smallest subset that would yield reasonable performance comparable to the full consensus signature. For each of the five lots, RFE was iteratively done with decreasing numbers of genes all the way to one gene, and a score was assigned to each gene based on how many times it appeared in each iteration of RFE. The Mean and Median of these scores was calculated to rank the genes and subsets of 5, 10, 15 and 20 were tested on the remaining two testing lots. Median Precision-Recall area under the curve (PR AUC) of these two testing lots was used to rank the subsets and ultimately a balance of size of gene-list to performance was utilized to pick the final gene list. Relative importance of individual genes (rank) within the context of each gene list was assessed using a Leave-One-Out (LOO) approach. In this methodology7, a gene was excluded from the list and the performance metrics (PR AUC, Precision, Recall) were obtained on the test IP lots. The ranks for each gene were then derived by sorting the median PR AUC across the test lots in ascending order, since the lower the performance metrics were for testing without a gene, the more important that gene is to the overall list. The interpretation of the rank of a gene islimited solely to the context of a gene list. Within this context, a gene that is ranked as 1 is the most important, 2 is second most important, and so on, and so forth. One gene (TYROBP)was manually added back in for better discrimination from NK / NKT cells.ResultsLinking Infusion Product Characteristics to Clinical Outcome in Allogeneic CAR T therapy

[0273] Understanding the association of Infusion Product (IP) characteristics with clinical outcomes is inherently difficult in allogeneic CAR T therapy, because each IP lot is given to multiple patients and resulting in a range of outcomes. To circumvent this challenge, patientlevel information of expanding IP T cell receptor (TCR) clonotypes following infusion of allogeneic CAR T products and the consistency of expansion of IP clonotypes across patients given the same IP lot were utilized to define the concept of preferentially expanding clones. Thus identifying clones for each IP lot that preferentially expanded in multiple patients allowed these clones to be traced back to multimodal single cell characterization of the IP and interrogate the phenotypic differences between the cells that expanded preferentially and ones that did not.Peripheral Blood Expanding IP Clones are Identifiable in Solid Tumor Samples

[0274] To answer the question about the relevance of the preferentially expanding clones in peripheral blood to tumor killing and clinical efficacy, available post-infusion clear cell renal cell carcinoma (ccRCC) biopsy samples from patients infused with the same CART lot were analyzed using TCRseq and compared to corresponding peripheral blood samples. In all cases. IP clones expanding in blood were observed to be present in the corresponding tumor samples, albeit to varying degrees. Using a similar definition of preferentially expanding clones for the IP lot based on expansion of clones in tumor samples, it was found that a majority of tumor preferentially expanding clones were also marked as preferentially expanding in peripheral blood (FIGs.2A-2B). Overall, these results indicate that peripherally expanding clones in the blood do traffic to the tumor sites and potentially participate in tumor killing.

[0275] In some embodiments, the engineered immune cell clones identified in patient samples selected from post-infusion tumor samples and bone marrow aspirate samples correspond predominantly to cells having an effector memory or CEC-like phenotype, as determined by one or more of the gene signatures or corresponding protein markers disclosed herein (FIG.2C-2D). In some embodiments, such findings support that the signaturesdisclosed herein effectively identify cells capable of trafficking to disease sites and preferentially expanding in vivo.Phenotypic Characteristics of Preferentially Expanding Clones

[0276] By mapping preferentially expanding IP clones identified from patient samples using TCRseq to the corresponding single cell data for the IP lot, clusters within the IP lots that were enriched for expanding clones were annotated. These clusters were predominantly CD8 T cells, and qualitatively appeared to show highly consistent gene and surface protein signatures across multiple IP lots (FIGs. 1A-1E). The combination of markers highly expressed on expanding clones seemed to suggest an effector-memory like phenotype on the expanding clones based on literature. The markers that qualitatively suggested a T cell effector-memory like phenotype are GZMB, GZMH, GZMK, PLEK, EOMES, CCL3, CCL4 and KLRG1 (FIGs. 1F-1I). Analysis and comparison of RNA and protein expression show the expanding clones have a highly similar signatures across the 5 lots (of anti-BCMA Lots 1 and 2 and anti-CD19 Lots 1-3), both at RNA and protein level. This allowed for the identification and testing of gene signatures that could be used to robustly measure expanding clones in new' IP lots. This shows that expanding IP clones can be identified from patient samples (engineered immune cells and donor cells) using the gene signatures described herein.Gene Signature Can Accurately Identify Preferentially Expanding Clones in IP lots

[0277] A robust machine-learning based approach to identify consistent signatures of genes or surface proteins indicated that signatures of genes showed better performance for predicting preferentially expanding clones in completely new IP lots. Subsequent efforts were focused on single cell gene expression. Using a multi-step machine learning approach, a 50-gene signature w as identified across four training IP lots. Two genes (TRDV2 and TRGV9) were added manually for better discrimination w ith Gamma-delta T cells, to yield a 52-gene signature (Table 1). The identified 52-gene signature was independently validated for its ability to accurately mark clinically expanding clones (as inferred by TCRseq in patient samples) in three additional IP lots (FIGs. 3A-3C, Table 22). The 52-gene signature can be used to predict the expanding clone cells in the IP lot and then compare that against the ground truth of actual expanding clone cells as inferred by TCR sequencing to get an estimate of performance (Precision, Recall, PR AUC, etc.)Table 22: Performance metrics for validation of 52 gene signature

[0278] The 52 gene signature contained 34 genes that are highly expressed on the expanding clone cells, and 18 genes that are lowly or not expressed on the expanding clone cells (Tables 3A and 3B, respectively). The signature represented markers involved in several different functions, including but not limited to cell lineage identification, cytotoxic / effector function, cell growth and proliferation, cell adhesion and migration, chemokines, MHC, metabolic genes (Table 1).

[0279] PR AUC (Area Under the Precision-Recall curve) quantifies how well a model distinguishes between positive and negative classes, considering both precision and recall. A higher PR AUC indicates a better-performing model. Precision is the proportion of true positive predictions out of all positive predictions made by the model. Recall (sensitivity / true positive rate) is the proportion of true positive predictions from all actual positive samples in the dataset. It measures the model’s ability to identify all positive instances and is critical when the cost of false negatives is high. Based on Table 22 and FIGs. 4A-4C the 52 gene set has a PR-AUC ranging from 0.84-0.77 across the three test lots illustrating the 52 gene set can be used to identify preferentially expanding T cells across different CAR T cell treatments. The precision and recall values in Table 22 further support the conclusion that the 52 gene set can be used to identify preferentially expanding engineered T cells across different CAR T cell treatments.

[0280] Additional steps to identify a subset of the 52 genes that could perform comparably to the full set using five of the IP lots yielded a 16-gene signature (Tables 4A and 4B) and was validated in the remaining two IP lots (FIGs. 5A-5D, Table 23). FIG. 5C shows that the 16 gene signature can identify preferentially expanding clones in anti-CD19 I Lot 1. FIG. 5D shows that the 16 gene signature can identify preferentially expanding clones in anti-CD70 Lot 2. Additional gene signatures were tested ranging from 20 genes down to 5 genes to identify a gene signature that marks preferentially expanding engineered T cells across different IP lots (Table 23)Table 23: Performance metrics for validation of 16 gene signature

[0281] In some embodiments, preferentially expanding cells and cells positive for one or more of the gene signatures disclosed herein are enriched in CD8+ T cell populations having an effector memory phenotype or a terminal effector-like phenotype, including donor PBMC populations and engineered immune cell populations (FIG.6B).

[0282] The 16 gene signature contained 13 genes that are highly expressed on the expanding clone cells, and 3 genes that are lowly or not expressed on the expanding clone cells (Tables 4 A and 4B, respectively). The signature represented markers involved in several different functions, including but not limited to cell lineage identification, cytotoxic / effector function, cell growth and proliferation, cell adhesion and migration, chemokines, MHC, metabolic genes (Table 2).

[0283] Based on Table 24 the 16 gene set has a PR-AUC ranging from 0.80-0.72 across the two test lots showing the 16 gene set can be used to identify preferentially expanding engineered T cells across different CAR T cell treatments. The precision and recall values in Table 24 further support the conclusion that the 16 gene set can be used to identify preferentially expanding engineered T cells across different CAR T cell treatments.Table 24: Metrics for testing of subsets of 52 gene signature

[0284] Table 24 shows that the additional gene signatures generated from subsets of genes in the 52 gene signature are also able to identify preferentially expanding clones in IP lots. Gene signatures as large as 20 were validated in two different IP lots (anti-CD19 IP Lot 1 and anti-70 IP Lot 2) and could identify preferentially expanding clones based on the PR-AUC of 0.84-0.77. A similar trend was seen with gene signatures of 15, 10 and 5 genes. As discussed above, in certain gene signatures one gene (TYROBP) was manually added back in for better discrimination fromNK / NKT cells. Gene signatures where TYROBP was added are denoted with ’ _plus" and those where TYROBP was not added lack ‘“_plus”. For example, rfe niean top l5 plus was the top 15 genes identified by median PR AUC across the test lots (Table 2 IB) and then TYROBP was added manually for better discrimination from NK / NKT cells.. This data shows that additional gene signatures can be generated from the larger 52 gene signature to identify preferentially expanding clones in IP lots. This shows that these additional gene signatures can be used to identify preferentially expanding immune cells in engineered immune cells in an engineered immune cell population and donor cells in a donor cell population.Example 2: Single Cell Characterization of Expanding Clone Phenotypes in Donor PBMCs of clinical IP lots

[0285] This example describes the use of single cell sequencing to identify expanding clone phenotypes in donor PBMCs of clinical IP lots based on the 52 and 16 gene signatures described in Example 1.

[0286] Samples for this work will be derived from donor polymorphonuclear cells (PBMCs) across different patients. To identify' the expanding clone phenotypes in donor PBMCs of clinical IP lots single cell sequencing will be performed. Donor PBMCs of clinical IP lots will be thawed and washed in X-vivo media (Lonza, Cat#04-380Q). PBMCs will be resuspended in cell staining buffer (BioLegend, Cat#420201) and stained with TotalSeq-C antibody cocktail (BioLegend, custom order -204 antibodies) following the manufacture’sprotocol. 20,000 cells will be targeted for each sample. Single cell antibody-derived tags (ADTs), V(D)J, and gene expression libraries will be prepared with Chromium Next GEM Single Cell 5' HT Reagent v2 kits (lOx Genomics) following the manufacturer's User Guide. Library samples will be sequenced on NextSeq2000 (Illumina). Processing, fdtering, clustering and annotation of the multimodal data will be performed in R using Seurat (v5.0.1). Enrichment of preferentially expanding clones at the cluster level will be assessed using a Fisher’s test, and expanding clone clusters will be identified for each IP lot. Dimensionality7reduction and visualization algorithm Uniform Manifold Approximation and Projection (UMAP) will be used to visualize the IP single cell data and highlight clusters enriched with expanding clones. Differential expression analyses will be performed to compare expanding clone clusters to the ones that did not expand. Heatmaps will be used to visualize and qualitatively assess consistency of phenotypic signatures across IP lots.

[0287] The gene signature will be used to identify the abundance of preferentially expanding clones in donor PBMCs of clinical IP lots. Based on this analysis with the gene signatures described herein the proportion of donor PBMCs of clinical IP lots with the expanding phenoty pe will be calculated.

[0288] This example demonstrates that the gene signatures described herein can be resolved at single-cell resolution within donor PBMCs and highlights its utility for deconvoluting immune state and function at a cellular level. Such information may be used in downstream diagnostic or therapeutic applications to stratify donor PBMC population based on the preferentially expanding phenotype identified in Example 1.Example 3: Single Cell Characterization of Expanding Clone Phenotypes in Patient samples post-infusion

[0289] This example describes the use of single cell sequencing to identify expanding clone phenoty pes in patient samples post-infusion based on the gene signatures described herein.

[0290] Post-infusion CAR T samples will be thawed and washed in X-vivo media (Lonza, Cat#04-380Q). Cells will be resuspended in cell staining buffer (BioLegend, Cat#420201) and stained with Total Seq-C antibody cocktail (BioLegend, custom order -204 antibodies) following the manufacture’s protocol. 20,000 cells will be targeted for each sample. Single cell antibody -derived tags (ADTs), V(D)J, and gene expression libraries will be prepared with Chromium Next GEM Single Cell 5' HT Reagent v2 kits (lOx Genomics) following the manufacturer's User Guide. Library samples will be sequenced on NextSeq2000 (Illumina). The data will be processed using Cellranger multi pipeline and aligned with a custom GRCh38 human genome reference containing the CAR construct. Processing, filtering,clustering and annotation of the multimodal data will be performed in R using Seurat (v5.0.1 ). Preferentially expanding clones will be identified from patients using TCRseq for each IP lot by mapping to the corresponding single cell TCR data for the IP using the CDR3 amino acid sequences. Enrichment of preferentially expanding clones at the cluster level will be assessed using a Fisher’s test, and expanding clone clusters will be identified for each IP lot. Dimensionality reduction and visualization algorithm Uniform Manifold Approximation and Projection (UMAP) will be used to visualize the IP single cell data and highlight clusters enriched with expanding clones. Differential expression analyses will be performed to compare expanding clone clusters to the ones that did not expand. Heatmaps will be used to visualize and qualitatively assess consistency of phenotypic signatures across IP lots.

[0291] Each of the gene signatures described herein will be independently validated for its ability to accurately mark clinically expanding clones (as inferred by TCRseq in patient samples) in patient samples. PR AUD. Precision and recall will be measured in patient samples.

[0292] This example demonstrates that the 52 and 16 gene signature can be resolved at singlecell resolution within patient samples post-infusion and highlights its utility for deconvoluting immune state and function at a cellular level. Such information may be used in downstream diagnostic or therapeutic applications to stratify patient samples post-infusion based on the preferentially expanding phenoty pe identified in Example 1.Example 4: Assay and measurement of identified 52 and 16-gene signature in bulk populations by RNA-seq, NanoString and / or qPCR

[0293] This examples describes the use of RNA-seq. Nanostring and / or qPCR to measure the expression of the gene signatures disclosed herein in bulk cell populations.

[0294] For this experiment, bulk RNA will be extracted from the immune cell population using a silica-membrane-based column purification system. RNA quality can be assessed using a Bioanalyzer or Nanodrop. To assess gene expression, three independent assays will be performed on separate aliquots of total RNA:1. RNA-Seq Analysis- RNA seq libraries will be prepared using a mRNA-seq kit (e.g. Illumina TruSeq) and and sequenced on an Illumina NovaSeq platform to a depth of ~40 million paired-end reads per sample. Reads will be aligned to the human genome (GRCh38) using STAR, and gene-level expression will be quantified using feature Counts. Normalized expression (e.g., TPM or FPKM) values will be extracted for the gene signature panels. Differential expression and clustering analyses will be conducted using DESeq2 and Seurat.2. Nanostring Assay-custom Nanostring nCounter CodeSets will be designed to target each of the gen signatures disclosed herein. Approximately 100 ng of total RNA per sample will be hybridized to the CodeSet probes and analyzed using the nCounter Digital Analyzer system. Expression counts will be normalized to internal housekeeping genes (e.g. GAPDH, ACTB, B2M) and analyzed using nSolver software.3. Quantitative PCR (qPCR)- TaqMan-based or other probe based qPCR assays will be used to validate expression of genes in each of the gene signatures disclosed herein. cDNA will be synthesized using a high-capacity reverse transcription kit. Expression will be normalized to endogenous control genes and analyzed using the AACt method.

[0295] Expression profding of the gene signatures is expected to assess feasibility of selecting this phenotypic population in donor cells, in CAR T manufacturing process or drug product lots and to demonstrate correlation of the phenotype with potency and release assays.

[0296] The analysis described above may be performed on donor PBMCS prior to engineering to identify the proportion of donors PBMCs that have the preferentially expanding gene signature. The analysis described above may be performed on engineered T cells at any point in manufacturing process to identify the proportion of engineered T cells that have the preferentially expanding gene signature. The analysis may be performed at any point after engineered immune cells are infused in the patient to identify7the proportion of engineered immune cells in vivo that have the preferentially expanding gene signature. Additional examples of when the bulk RNA analysis can be performed in the process include: a) Infusion Product lots, resting and post-target exposureb) Donor cellsc) In process samples during CAR T productiond) Long-term potency assays (single and serial re-stimulation)e) Short-term cytotoxicity assaysf) In vivo tumor models

[0297] The analysis can also be run before and after the patient is treated with an additional compound (e g., Interleukin, Chemotherapy agent or antibody based therapy) to determine how the additional compound changes the proportion of engineered immune cells in vivo that have the preferentially expanding gene signature. This may allow for the identification of additional factors that can be used in combination with engineered immune cells to increaseor decrease the proportion of engineered immune cells in vivo that have the preferentially expanding gene signature.

[0298] The analysis can also be run before and after the isolated engineered immune cells are treated with an additional compound (e.g.. Interleukin, Chemotherapy agent or antibody based therapy) to determine how the additional compound changes the proportion of engineered immune cells that have the preferentially expanding gene signature. This may allow for the identification of additional factors that can be used in combination with engineered immune cell to increase or decrease the proportion of engineered immune cells in vitro that have the preferentially expanding gene signature.

[0299] This example shows that RNAseq, Nanostring and qPCR can be used to assess feasibility' of selecting this phenotypic population in donor cells, in CAR T manufacturing process or IP lots and to demonstrate correlation of the phenotype with potency and release assays.Example 5: 4. Assay of select cell surface protein markers derived from the 52-or 16-gene signature

[0300] This example describes measuring select cell surface protein markers derived from the gene signatures disclosed herein by flow cy tometry' to identify correlated surface marker combinations that can be used to identify preferentially expanding clone phenotypes.

[0301] For this experiment immune cells will be harvested for flow cytometry (FACS) analysis to evaluate expression of a panel of proteins corresponding to cell surface expressed proteins present in the 52-gene and 16-gene signature (Tables 3 and 4). The following proteins from the 52-gene signature may be evaluated by FACs: KLRB1, HLA-DPA1, TNFRSF18, ITGB2. CD8a, ANXA1. TNFRSF4, CD74, TYROBP. LAG3, CD99. HLA-DR, TRDV2, CD8B, ITGB1, HLA-DRB1, TIGIT, TRGV9, HLA-DRB5, and KLRC1. The following proteins from the 16-gene signature may be evaluated by FACs: HLA-DPA1, HLA-DRB5, TNFRSF18, CD8A, TRDV2, CD8B, TYROBP, LAG3, and HLA-DRB1. FACs can be used to evaluate the cell surface level of expression of any of the genes within any of the gene signatures disclosed herein and any combination thereof.

[0302] The FACs analysis described above may be performed on donor PBMCS prior to engineering to identify' the proportion of donors PBMCs that express the surface proteins of the preferentially expanding gene signature. The analysis described above may be performed on engineered T cells at any point in manufacturing process to identify’ the proportion of engineered T cells that express the surface proteins of the preferentially expanding gene signature. The analysis may be performed at any point after engineered immune cells areinfused in the patient to identify the proportion of engineered immune cells in vivo that express the surface proteins of the preferentially expanding gene signature. Additional examples of when the bulk FACs analysis can be performed in the process include:a) Infusion Product lots, resting and post-target exposureb) Donor cellsc) In process samples during CAR T productiond) Long-term potency assays (single and serial re-stimulation)e) Short-term cytotoxicity assaysf) In vivo tumor models

[0303] The FACs analysis can also be run before and after the patient is treated with an additional compound (e.g., Interleukin, Chemotherapy agent or antibody based therapy) to determine how the additional compound changes the proportion of engineered immune cells in vivo that express the surface proteins of the preferentially expanding gene signature. This may allow for the identification of additional factors that can be used in combination with engineered immune cells to increase or decrease the proportion of engineered immune cells in vivo that have the preferentially expanding gene signature.

[0304] Signature positive cells are anticipated to preferentially expand in downstream in vitro assays and correlate with in vivo expansion and efficacy in patients.Example 6: In vitro and / or in vivo experiments to further characterize cell populations with gene signature.

[0305] This example will describe the in vitro and in vivo testing of isolated expanding clone phenotypic populations as drug products to assess potency of this population relative to other phenotypic populations.

[0306] For this experiment, engineered T cells from different IP lots will be characterized for the expression of any one of the gene signatures disclosed herein and isolated using FACs as described above. At least two populations of immune cells will be collected from FACs 1) engineered immune cell populations that are positive for one or more of the gene signatures disclosed herein and 2) engineered immune cell populations that are negative for one or more of the gene signatures disclosed herein. Additional groups of immune cells could be sorted from the populations based on the level of expression of the gene signatures or based on a subset of genes in the respective gene signatures. After FACs the isolated engineered immune cell populations will be analyzed using various in vitro functional assays including cytotoxicity, mitochondrial fitness, cytokine secretion profiling and in vivo tumor studies.

[0307] Cytotoxicity. A short-term killing assay (STKA) and a long-term killing assay (LTKA) will be used to evaluate and compare CAR T cell cytotoxicity between different cell populations.

[0308] STKA: Engineered immune cells that are positive for the gene signature will be compared to engineered immune cell populations that are negative for the gene signature. After FACS, isolated engineered immune cell populations will be analyzed for viability and cell count with a Vi-Cell XR analyzer from Beckman Coulter. STKA will be set up in cell culture plates and the same number of GFP-LUC+ target cells will be co-cultured with each of the isolated immune cell populations. The number of engineered immune cells will change the effector cell: target cell ratios of 10:1, 5:1, 2.5:1, 1.25:1, 0.625:1, 0.3:1 and 0.15:1. Triplicate wells will be prepared for each condition and plates will be kept in 37 °C, CO2 supplement incubator after setup. After overnight incubation (about 24 hours), cytotoxicity will be measured by measuring the luciferase signal from target cells using Promega Bright-Glo Luciferase Assay System on Promega GloMax instrument. A higher luciferase signal indicates low cytotoxicity of the isolated engineered immune cell populations. It is predicted that the engineered immune cell populations that are positive for the gene signature will show higher cytotoxicity (lower Luciferase measurement) compared to engineered immune cell populations that are negative for the gene signature.

[0309] LTKA: The same cell population tested in the STKA can also be tested in the LTKA. After FACS, isolated engineered immune cell populations will be analyzed for viability and cell count with a Vi-Cell XR analyzer from Beckman Coulter. The LTKA will be set up in cell culture plate and the same number of GFP-LUC+ target cells will be co-cultured with each of the isolated immune cell populations. The number of engineered immune cells will change to effector cell: target cell ratios of 10:1, 5:1, 2.5:1, 1.25:1, 0.625:1, 0.3:1 and 0.15: 1. Triplicate wells will be prepared for each condition and plates will be kept in 37 °C, CO2 supplement incubator after setup. Every 2 - 3 days, half of the cells will be transferred to a new796-well flat-bottom plate and re-challenged with the same amount of target cells as setup to evaluate long-term cytotoxicity and persistency. The other half of the cells will be used to measure cytotoxicity7but measuring luciferase signal using Promega Bright-Glo Luciferase Assay System on Promega GloMax instrument. The LTKA is continued until no cytotoxicity is observed. A higher luciferase signal indicates low cytotoxicity of the isolated engineered immune cell populations. It is predicted that the engineered immune cell populations that arepositive for the gene signature will show higher cytotoxicity (lower Luciferase measurement) compared to engineered immune cell populations that are negative for the gene signature.

[0310] Mitochondrial Fitness: The mitochondrial fitness of isolated engineered immune cells that are positive for the gene signature and isolated engineered immune cell populations that are negative for the gene signature will be characterized with Agilent Seahorse XF Cell Mito Stress Test Kit. Isolated engineered immune cells from both populations will be checked for cell viability and cell count with Vi-Cell XR analyzer from Beckman Coulter. Cell concentrations will be adjusted in RIO media (RPMI + 10 % HI-FBS + lx non-essential amino acid + lx sodium pyruvate) and rest in 37°C, CO2 supplement incubator for at least 1 hour. After incubation, assay will be conducted by following the manufacturer’s protocol and data will be collected using Seahorse XFe96 Analyzer. Spare respiratory capacity7(SRC) will be measured with the instrument indicating how much extra energy7cells can provide upon emergency and higher SRCs being indicative of cells with fitter mitochondrial function. It is predicted that isolated engineered immune cells that are positive for the gene signature will have higher mitochondrial fitness than isolated engineered immune cell populations that are negative for the gene signature.

[0311] Cytokine Secretion Profiling: Cytokine secretion at the single cell level will be measured to generate a polyfunctional strength index (PSI) (Isoplexis Isocode technology) of isolated engineered immune cells that are positive for the gene signature compared to isolated engineered immune cell populations that are negative for the gene signature. Briefly, isolated engineered immune cells from both populations with be stimulated with Staphylococcal enterotoxin B (SEB) or TransAct. SEB is antigen that can stimulate immune cells in a nonspecific and robust manner. TransAct is designed to stimulate and expand T cells in vitro. TransAct works by using a nanomatrix conjugated with anti-CD3 and anti-CD28 agonists to provide signals for T cell activation. Isolated engineered immune cells will be stimulated for 24hrs and then stained with Stain A and loaded onto chips. Data will be collected on IsoLight. Using the formula below, PSI will measure the cytokine secretion capacity7at single cell level and the intrinsic differences between the different isolated engineered CR-T cells in cytokine secretion.

[0312] It is predicted that isolated engineered immune cells that are positive for the signature will have higher on levels than isolated engineered immune cell populations that are negative for the gene signature. Tables 3 and 4 show specific cytokines and chemokines that are part of the 52- or 16-gene signatures.

[0313] In vivo'. To test the anti-tumor effects of the different isolated engineered immune cells described above, tumor bearing NSG mice will be used. Tumor cells positive for the antigen targeted by the isolated engineered CAR T cell will be engrafted into NSG mice. Immediately before implanting, tumor cells will be mixed 1:1 with BD Matrigel Matrix (cat# 354234) and a set amount will be injected per mouse subcutaneously. Tumor growth will be measured by caliper measurements using a digital caliper starting from Day 5 post-implantation. Tumor size will be calculated using the formula Tumor volume = (widthA2 x length / 2). Mice will be randomized into at least 2 different groups based on tumor volume about two weeks postimplantation. One day after mice are randomized, mice will be injected via tail vein with engineered immune cell populations that are positive for the 52- or 16-gene signature or engineered immune cell populations that are negative for the 52- or 16-gene signature. Tumors will be measured every 3-4 days until the end of the study. It is predicted that the engineered immune cell populations that are positive for the 52- or 16-gene signature will show higher tumor cell cytotoxicity (reduced tumor volume) compared to engineered immune cell populations that are negative for the 52- or 16-gene signature.

[0314] While the invention has been described in detail with reference to specific examples, it will be apparent to one skilled in the art that various modifications can be made within the scope of this invention. Thus, the scope of the invention should not be limited by the examples described herein, but by the claims presented below.

Claims

CLAIMSWe claim:

1. An immunotherapy composition, comprising an effector T cell population, wherein the cell population comprises cells expressing, detectable as a polynucleotide and / or a protein, one or more upregulated genes of upregulated genes provided in Table 19A or one or more downregulated genes of downregulated genes provided in Table 19B.

2. The composition of claim 1, wherein the one or more genes of Table 19A are each independently expressed at a level higher than a control level of expression in a control cell population having lower potency than the effector T cell population.

3. The composition of claim 1, wherein the one or more genes of Table 19B are each independently expressed at a lower level than a control level of expression in a control cell population having lower potency than the effector T cell population.

4. The composition of claim 2 or claim 3, wherein the one or more upregulated genes and the one or more dow nregulated genes comprises at least set of genes in a numbered row of Table 21A, Table 21B, Table 21C, and Table 21D5. The composition of any one of claims 1-4, wherein the effector T cell population comprises at least 5 precent (%) or between about 1 % and 10 % of cells expressing the one or more genes.

6. The composition of any one of claims 1-5, wherein the effector T cell population is a chimeric antigen receptor T (CAR T) cell population.

7. The composition of any one of claims 1-6, wherein the expression of one or more genes is detectable as polynucleotide, optionally by quantitative reverse transcription polymerase chain reaction (qRT-PCR).

8. The composition of any one of claims 1-6, wherein the expression of one or more genes is detectable as protein, optionally by flow cytometry.

9. The composition of any one of the previous claims, wherein the effector T cell population has improved in vitro functionality as compared to an additional effector T cell population that does not express one or more of upregulated genes provided in Table 19A or expresses one or more of downregulated genes provided in Table 19B.

10. The composition of claim 9, wherein the improved in vitro functionality’ comprises one or more of improved in vitro cytotoxicity, improved cell fitness, and reduced cytokine secretion.

11. The composition of claim 10, wherein the cytotoxicity is demonstrated by an in vitro killing assay.

12. The composition of claim 10, wherein the cytotoxicity is demonstrated by in vitro killing assay that comprises killing of cells that express a target of a CAR.

13. The composition of claim 11 or 12, wherein the in vitro killing assay is a long-term killing assay.

14. The composition of claim 11 or 12, wherein the in vitro killing assay is a short-term killing assay.

15. The composition of any one of claims 1-14, wherein the effector T cell population is an effector memory T cell population.

16. A method of treating a disease or disorder in a patient, the method comprising administering to the patient the composition of any one of claims 1-15.

17. The method of claim 16, wherein the patient has, or is suspected of having cancer.

18. The method of claim 17, wherein the cancer is selected from the group consisting of leukemia, lymphoma, multiple myeloma, melanoma, breast cancer, lung cancer, colorectal cancer, pancreatic cancer, ovarian cancer, prostate cancer, and glioblastoma.

19. A method of selecting a donor cell population, comprising: detecting in a plurality’ of donor cell populations one or more genes of upregulated genes provided in Table 19A or downregulated genes provided in Table 19B or a set of upregulated and downregulated genes provided in Table 21A-D; and selecting at least one donor cell population from the plurality as having: detectable expression of the one or more genes or set of genes, higher expression of the one or more upregulated genes or set of upregulated genes and / or lower expression of the one or more downregulated genes or set of downregulated genes than a reference cell population, and / or higher expression of the one or more upregulated genes or set of upregulated genes and / or lower expression of the one or more doyvnregulated genes or set of downregulated genes than other members of the plurality.

20. The method of claim 19, wherein the method comprises, before the selecting of at least one donor cell population, introducing a polynucleotide sequence encoding an exogenous gene.

21. The method of claim 20, wherein the exogenous gene comprises a chimeric antigen receptor (CAR).

22. The method of claim 21, wherein the CAR comprises a transmembrane domain, a costimulatory domain and a signaling domain.

23. The method of claim 19, wherein the method comprises, after the selecting of at least one donor cell population, introducing a polynucleotide sequence encoding an exogenous gene.

24. The method of claim 23, wherein the exogenous gene comprises a chimeric antigen receptor (CAR).

25. The method of claim 24, wherein the CAR comprises a transmembrane domain, a costimulatory' domain and a signaling domain.

26. The method of any one of claims 19-25, wherein the expression of one or more genes is detectable as polynucleotide, optionally by quantitative reverse transcription polymerase chain reaction (qRT-PCR).

27. The method of any one of claims 19-25, wherein the expression of one or more genes is detectable as protein, optionally by flow cytometry.

28. A method of manufacturing engineered immune cells comprising: detecting in a plurality of immune cell populations one or more genes of upregulated genes provided in Table 19A or down regulated genes provided in Table 19B or a set of upregulated and downregulated genes provided in Table 21A-D; and selecting at least one immune cell population from the plurality as having: detectable expression of the one or more genes or set of genes, higher expression of the one or more upregulated genes or set of upregulated genes and / or lower expression of the one or more downregulated genes or set of downregulated genes than a reference cell population, and / or higher expression of the one or more upregulated genes or set of upregulated genes and / or lower expression of the one or more downregulated genes or set of downregulated genes than other members of the plurality wherein the selected immune cell population is modified to express an exogenous nucleic acid.

29. The method of claims 28, w herein the exogenous nucleic acid comprises a chimeric antigen receptor (CAR) nucleic acid sequence.

30. The method of claim 29, wherein the CAR nucleic acid sequence comprises a transmembrane domain nucleic acid sequence, a costimulatory domain nucleic acid sequence and a signaling domain nucleic acid sequence.

31. The method of any one of claims 28-30, wherein the expression of one or more genes is detectable as polynucleotide, optionally by quantitative reverse transcription polymerase chain reaction (qRT-PCR).

32. The method of any one of claims 28-30, wherein the expression of one or more genes is detectable as protein, optionally by flow cytometry.

33. The method of any one of claims 28-32, wherein the engineered immune cells are T cells.

34. The method of claim 33, wherein the T cells are CAR T cells.

35. The method of claim 33 or 34, wherein the T cells are effector memory T cells.